IN VIVO IMAGING OF SULFOTRANSFERASES

IMAGERIE IN VIVO DE SULFOTRANSFERASES

English Abstract

Radiolabeled tracers for sulfotransferases (SULTs), their synthesis, and their
use are provided. Included are substituted
phenols, naphthols, coumarins, and flavones radiolabeled with 18F, 123I, 124I,
125I, or 11C. Also provided are in vivo techniques
for using these and other tracers as analytical and diagnostic tools to study
sulfotransferase distribution and activity, in health and
disease, and to evaluate therapeutic interventions.

French Abstract

L'invention concerne des traceurs radiomarqués de sulfotransférases (SULT), leur synthèse et leur utilisation. L'invention concerne des phénols, naphtols, coumarines et flavones substitués radiomarqués avec 18F, 123I, 124I, 125I ou 11C. L'invention concerne également des techniques in vivo permettant d'utiliser ces traceurs et d'autres traceurs en tant qu'outils analytiques et de diagnostic pour étudier une distribution et une activité de sulfotransférases, chez des êtres sains et malades, et pour évaluer des interventions thérapeutiques.

Claims

WHAT IS CLAIMED IS:
1. A method of assessing sulfotransferase (SULT) distribution or activity in a
mammal,
in vivo, comprising:
administering to the mammal a bolus of a radiolabeled tracer;
generating radiographic data indicative of tracer uptake in the mammal by
scanning
the mammal using a radiographic technique; and
using the radiographic data to assess SULT distribution or activity in the
mammal;
wherein the radiolabeled tracer comprises at least one compound selected from
the
group consisting of
(a) phenols having the formula (1)
<IMG>
where A1 is OH and each of A2 - A6 is independently selected from the group of
moieties
denoted by "K" (defined below), provided that at least one of A2 - A6 is or
contains a
radioisotope; or A1 and A3 are both OH and each of A2, A4 - A6 is
independently selected
from the group of moieties denoted by K, provided that at least one of A2, A4 -
A6 is or
contains a radioisotope;
(b) naphthols having the formula (2)
<IMG>
where B1 is OH and each of B2 - B8 is independently selected from the group of
moieties
denoted by K, provided that at least one of B2 - B8 is or contains a
radioisotope; or B2 is OH
and each of B1, B3 - B8 is independently selected from the group of moieties
denoted by K,
provided that at least one of B1, B3 - B8 is or contains a radioisotope; or B1
and B3 are each
OH and each of B2, B4 - B8 is independently selected from the group of
moieties denoted by
K, provided that at least one of B4 - B8 is or contains a radioisotope;
(c) coumarins having the formula (3)
--32--

<IMG>
where X and Y are, independently, O, S, or N-R1 (wherein R1 is H, alkyl, aryl,
[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl,]
[125I]iodoalkyl, or [125I]iodoaryl); and wherein
C3 is OH and each of C1 - C2, C4 - C6 is independently selected from the group
of moieties
denoted by K; or
C4 is OH and each of C1 - C3, C5 - C6 is independently selected from the group
of moieties
denoted by K; or
C5 is OH and each of C1 - C4, C6 is independently selected from the group of
moieties
denoted by K; or
C6 is OH and each of C1 - C5 is independently selected from the group of
moieties denoted by
K; or
C2 and C3 = OH and each of C1, C4 - C6 is independently selected from the
group of moieties
denoted by K; or
C2 and C4 = OH and each of C1, C3, C5 - C6 is independently selected from the
group of
moieties denoted by K; or
C2 and C5 = OH and each of C1, C3 - C4, C6 is independently selected from the
group of
moieties denoted by K; or
C2 and C6 = OH and each of C1, C3 - C5 is independently selected from the
group of moieties
denoted by K; or
C3 and C5 = OH and each of C1 - C2, C4, C6 is independently selected from the
group of
moieties denoted by K; or
C4 and C6 = OH and each of C1 - C3, C5 is independently selected from the
group of moieties
denoted by K; or
C2 = C3 = C5 = OH and each of C1, C4, C6 is independently selected from the
group of
moieties denoted by K; or
C2, C4 and C6 = OH and each of C1, C3, C5 is independently selected from the
group of
moieties denoted by K;
wherein in each case at least one of C1 - C6, X, or Y is or contains a
radioisotope;
(d) flavones having the formula (4)
--33--

<IMG>
where X and Y are, independently, O, S, or N-R1 (wherein R1 is H, alkyl,
aryl,[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl,]
[125I]iodoalkyl, or [125I]iodoaryl); and wherein
D3 is OH and each of D1 - D2, D4 - D6 is independently selected from the group
of moieties
denoted by K; or
D4 is OH and each of D1 - D3, D5 - D6 is independently selected from the group
of moieties
denoted by K; or
D5 is OH and each of D1 - D4, D6 is independently selected from the group of
moieties
denoted by K; or
D6 is OH and each of D1 - D5 is independently selected from the group of
moieties denoted
by K; or
D2 and D3 are OH and each of D1, D4 - D6 is independently selected from the
group of
moieties denoted by K; or
D2 and D4 are OH and each of D1, D3, D5 - D6 is independently selected from
the group of
moieties denoted by K; or
D2 and D5 are OH and each of D1, D3 - D4, D6 is independently selected from
the group of
moieties denoted by K; or
D2 and D6 are OH and each of D1, D3 - D5 is independently selected from the
group of
moieties denoted by K; or
D3 and D5 are OH and each of D1 - D2, D4, D6 is independently selected from
the group of
moieties denoted by K; or
D4 and D6 are OH and each of D1 - D3, D5 is independently selected from the
group of
moieties denoted by K; or
D2, D3 and D5 are OH, and D1, D4, D6 is independently selected from the group
of moieties
denoted by K; or
D2, D4 and D6 are OH, and D1, D3, D5 is independently selected from the group
of moieties
denoted by K;
wherein in each case at least one of D1 - D6, X, or Y is or contains a
radioisotope;
(e) fused ring compounds having the formula (5)
--34--

<IMG>
where Z is O, S, N-R1 (wherein R1 is H, alkyl, aryl, [11C]methyl,
[18F]fluoroalkyl,
[18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl, [124I]iodoalkyl,
[124I]iodoaryl,] [125I]iodoalkyl,
or [125I]iodoaryl), CH2, or CH=CH; and W is N or CH; and wherein
E2 is OH and each of E1, E3 - E5 is independently selected from the group of
moieties
denoted by K; or
E3 is OH and each of E1 - E2, E4 - E5 is independently selected from the group
of moieties
denoted by K; or
E4 is OH and each of E1 - E3, E5 is independently selected from the group of
moieties denoted
by K; or
E5 is OH and each of E1 - E4 is independently selected from the group of
moieties denoted by
K; or
E2 and E4 are OH and each of E1 - E4 is independently selected from the group
of moieties
denoted by K; or
E3 and E5 are OH and each of E1, E2, E4, is independently selected from the
group of moieties
denoted by K;
and wherein in each case at least one of E1- E5 or Z is or contains a
radioisotope;
(e') structurally related fused ring compounds in which E1 is a substituted
aryl group,
said compounds having the formula 5a:
<IMG>
where Z is O, S, N-R1 (wherein R1 is H, alkyl, aryl, [11C]methyl,
[18F]fluoroalkyl,
[18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl, [124I]iodoalkyl,
[124I]iodoaryl,] [125I]iodoalkyl,
or [125I]iodoaryl), CH2, or CH=CH; W is N or CH; and I' is H, alkyl, aryl,
[11C]methyl, 18F,
[18F]fluoroalkyl, [18F]fluoroaryl, 123I, [123I]iodoalkyl, [123I]iodoaryl,
124I, [124I]iodoalkyl,
[124I]iodoaryl,] 125I, [125I]iodoalkyl, or [125I]iodoaryl);
--35--

and wherein E2 is OH and each of E3 - E5 is independently selected from the
group of
moieties denoted by K; or
E3 is OH and each of E2, E4 - E5 is independently selected from the group of
moieties
denoted by K; or
E4 is OH and each of E2 - E3, E5 is independently selected from the group of
moieties denoted
by K; or
E5 is OH and each of E2 - E4 is independently selected from the group of
moieties denoted by
K; or
E2 and E4 are OH and each of E3, E5 is independently selected from the group
of moieties
denoted by K; or
E3 and E5 are OH and each of E2, E4 is independently selected from the group
of moieties
denoted by K;
and wherein in each case at least one of E1- E5, I', or Z is or contains a
radioisotope;
(f) imidazopyridines having the formula (6):
<IMG>
where F1 - F5 are the same as E1 - E5, and wherein at least one of F1 - F5 is
or contains a
radioisotope; or
(g) stilbenes having the formula (7):
<IMG>
where W1 and W2 are, independently, alkyl, aryl, or OH; and wherein
--36--

G3 is OH and each of G1 - G2, G4- G10 is independently selected from the group
of moieties
denoted by K; or
G2 and G4 are OH and each of G1, G3, G5 - G10 is independently selected from
the group of
moieties denoted by K; or
G3 and G8 are OH and each of G1 - G3, G4- G7, G9- G10 is independently
selected from the
group of moieties denoted by K; or
G2 = G4 = G8 = OH and each of G1, G3, G5 - G7, G9 - G10 is independently
selected from the
group of moieties denoted by K;
and wherein in each case at least one of G1 - G10 is or contains a
radioisotope.
and wherein, in each of compounds (a) - (g), K is selected from the group
consisting
of H; alkyl; aryl; 18F; [18F]fluoroalkyl; [18F]fluoroaryl; 123I;
[123I]iodoalkyl; [123I]iodoaryl; 124I;
[124I]iodoalkyl; [I24I]iodoaryl; 125I; [125I]iodoalkyl; [125I]iodoaryl; -OR1, -
SR1, or -NR1R2
(where R1 and R2 are independently H, alkyl, aryl, [11C]methyl,
[18F]fluoroalkyl;
[18F]fluoroaryl; [123I]iodoalkyl; [123I]iodoaryl; [124I]iodoalkyl;
[124I]iodoaryl; [125I]iodoalkyl;
or [125I]iodoaryl); -NO2; -CN; -S(=O)-R3 or -S(=O)2-R3 (where R3 is alkyl,
aryl, [11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl,
[125I]iodoalkyl, [125I] iodoaryl), or -OR4, -NR4R5, (wherein R4 and R5 are
independently H,
alkyl, aryl, [11C]methyl, [18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl,
[123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl, [125I]iodoalkyl, or [125I]iodoaryl)); and -
OC(=O)-R6, -SC(=O)-
R6, or -NH-C(=O)-R6 (where R6 is alkyl, aryl, [11C]methyl, [18F]fluoroalkyl,
[18F]fluoroaryl,
[123I]iodoalkyl, [123I]iodoaryl, [124I]iodoalkyl, [124I]iodoaryl,
[125I]iodoalkyl, or [125I]iodoaryl).
2. A method as recited in claim 1, wherein the mammal is selected from the
group
consisting of humans, non-human primates, rodents, wild-type rodents,
transgenic rodents
and knockout rodents, and dogs.
3. A method as recited in claim 1, wherein the radiographic technique
comprises
positron emission tomography (PET), micro-PET, or single-photon emission
computed
tomography (SPECT).
4. A method as recited in claim 1, further comprising administering to the
mammal at
least one actual or putative therapeutic agent, before, during, or after the
administration of the
radiolabeled tracer.
5. A method as recited in claim 4, wherein the therapeutic agent is
administered by
injection.
--37--

6. A method as recited in claim 1, wherein the radiographic technique
comprises one or
more computed tomographic scans of all or part of the mammal's body.
7. A method of evaluating therapeutic effect of an agent on a sulfotransferase
in a
mammal, comprising:
(A) administering a radiolabeled tracer to a mammal;
generating a first set of radiographic data by scanning the mammal using a
radiographic technique;
administering an actual or proposed therapeutic agent to the mammal,
intravenously,
orally, or by other suitable mode of delivery; generating a second set of
radiographic data by
scanning the mammal using a radiographic technique; and
comparing the first and second sets of radiographic data; or
(B) administering an actual or proposed therapeutic agent to the mammal,
intravenously, orally, or by other suitable mode of delivery;
administering to the mammal a radiolabeled tracer to the mammal; generating a
set of
radiographic data by scanning the mammal using a radiographic technique; and
comparing set of radiographic data to data obtained in the absence of the
agent;
wherein in (A) and (B) the radiolabeled tracer comprises at least one compound
selected from
the group consisting of
(a) phenols having the formula (1)
<IMG>
where A1 is OH and each of A2 - A6 is independently selected from the group of
moieties
denoted by "K" (defined below), provided that at least one of A2 - A6 is or
contains a
radioisotope; or A1 and A3 are both OH and each of A2, A4 - A6 is
independently selected
from the group of moieties denoted by K, provided that at least one of A2, A4 -
A6 is or
contains a radioisotope;
(b) naphthols having the formula (2)
--38--

<IMG>
where B1 is OH and each of B2 - B8 is independently selected from the group of
moieties
denoted by K, provided that at least one of B2 - B8 is or contains a
radioisotope; or B2 is OH
and each of B1, B3 - B8 is independently selected from the group of moieties
denoted by K,
provided that at least one of B1, B3 - B8 is or contains a radioisotope; or B1
and B3 are each
OH and each of B2, B4 - B8 is independently selected from the group of
moieties denoted by
K, provided that at least one of B4 - B8 contains a or is radioisotope;
(c) coumarins having the formula (3)
<IMG>
where X and Y are, independently, O, S, or N-R1 (wherein R1 is H, alkyl, aryl,
[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl,]
[125I]iodoalkyl, or [125I]iodoaryl); and wherein
C3 is OH and each of C1 - C2, C4 - C6 is independently selected from the group
of moieties
denoted by K; or
C4 is OH and each of C1 - C3, C5 - C6 is independently selected from the group
of moieties
denoted by K; or
C5 is OH and each of C1 - C4, C6 is independently selected from the group of
moieties
denoted by K; or
C6 is OH and each of C1 - C5 is independently selected from the group of
moieties denoted by
K; or
C2 and C3 = OH and each of C1, C4 - C6 is independently selected from the
group of moieties
denoted by K; or
C2 and C4 = OH and each of C1, C3, C5 - C6 is independently selected from the
group of
moieties denoted by K; or
--39--

C2 and C5 = OH and each of C1, C3 - C4, C6 is independently selected from the
group of
moieties denoted by K; or
C2 and C6 = OH and each of C1, C3 - C5 is independently selected from the
group of moieties
denoted by K; or
C3 and C5 = OH and each of C1 - C2, C4, C6 is independently selected from the
group of
moieties denoted by K; or
C4 and C6 = OH and each of C1 - C3, C5 is independently selected from the
group of moieties
denoted by K; or
C2 = C3 = C5 = OH and each of C1, C4, C6 is independently selected from the
group of
moieties denoted by K; or
C2, C4 and C6 = OH and each of C1, C3, C5 is independently selected from the
group of
moieties denoted by K;
wherein in each case at least one of C1 - C6, X, or Y is or contains a
radioisotope;
(d) flavones having the formula (4)
<IMG>
where X and Y are, independently, O, S, or N-R1 (wherein R1 is H, alkyl, aryl,
[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl,]
[125I]iodoalkyl, or [125I]iodoaryl); and wherein
D3 is OH and each of D1 - D2, D4 - D6 is independently selected from the group
of moieties
denoted by K; or
D4 is OH and each of D1 - D3, D5 - D6 is independently selected from the group
of moieties
denoted by K; or
D5 is OH and each of D1 - D4, D6 is independently selected from the group of
moieties
denoted by K; or
D6 is OH and each of D1 - D5 is independently selected from the group of
moieties denoted
by K; or
D2 and D3 are OH and each of D1, D4 - D6 is independently selected from the
group of
moieties denoted by K; or
D2 and D4 are OH and each of D1, D3, D5 - D6 is independently selected from
the group of
moieties denoted by K; or
--40--

D2 and D5 are OH and each of D1, D3 - D4, D6 is independently selected from
the group of
moieties denoted by K; or
D2 and D6 are OH and each of D1, D3 - D5 is independently selected from the
group of
moieties denoted by K; or
D3 and D5 are OH and each of D1 - D2, D4, D6 is independently selected from
the group of
moieties denoted by K; or
D4 and D6 are OH and each of D1 - D3, D5 is independently selected from the
group of
moieties denoted by K; or
D2, D3 and D5 are OH, and D1, D4, D6 is independently selected from the group
of moieties
denoted by K; or
D2, D4 and D6 are OH, and D1, D3, D5 is independently selected from the group
of moieties
denoted by K;
(e) fused ring compounds having the formula (5)
<IMG>
where Z is O, S, N-R1 (wherein R1 is H, alkyl, aryl, [11C]methyl,
[18F]fluoroalkyl,
[18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl, [124I]iodoalkyl,
[124I]iodoaryl,] [125I]iodoalkyl,
or [1251]iodoaryl), CH2, or CH=CH; and W is N or CH; and wherein
E2 is OH and each of E1, E3 - E5 is independently selected from the group of
moieties
denoted by K; or
E3 is OH and each of E1 - E2, E4 - E5 is independently selected from the group
of moieties
denoted by K; or
E4 is OH and each of E1 - E3, E5 is independently selected from the group of
moieties denoted
by K; or
E5 is OH and each of E1 - E4 is independently selected from the group of
moieties denoted by
K; or
E2 and E4 are OH and each of E1 - E4 is independently selected from the group
of moieties
denoted by K; or
E3 and E5 are OH and each of E1, E2, E4, is independently selected from the
group of moieties
denoted by K;
and wherein in each case at least one of E1- E5 or Z is or contains a
radioisotope;
--41--

(e') structurally related fused ring compounds in which E1 is a substituted
aryl group,
said compounds having the formula 5a:
<IMG>
where Z is O, S, N-R1 (wherein R1 is H, alkyl, aryl, [11C]methyl,
[18F]fluoroalkyl,
[18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl, [124I]iodoalkyl,
[124I]iodoaryl,] [125I]iodoalkyl,
or [125I]iodoaryl), CH2, or CH=CH; W is N or CH; and I' is H, alkyl, aryl,
[11C]methyl, 18F,
[18F]fluoroalkyl, [18F]fluoroaryl, 123I, [123I]iodoalkyl, [123I]iodoaryl,
124I, [124I]iodoalkyl,
[124I]iodoaryl,] 125I, [125I]iodoalkyl, or [125I]iodoaryl);
and wherein E2 is OH and each of E3 - E5 is independently selected from the
group of
moieties denoted by K; or
E3 is OH and each of E2, E4 - E5 is independently selected from the group of
moieties
denoted by K; or
E4 is OH and each of E2 - E3, E5 is independently selected from the group of
moieties denoted
by K; or
E5 is OH and each of E2 - E4 is independently selected from the group of
moieties denoted by
K; or
E2 and E4 are OH and each of E3, E5 is independently selected from the group
of moieties
denoted by K; or
E3 and E5 are OH and each of E2, E4 is independently selected from the group
of moieties
denoted by K;
wherein in each case at least one of E1- E5, I', or Z is or contains a
radioisotope;
(f) imidazopyridines having the formula (6):
<IMG>
--42--

where F1 - F5 are the same as E1 - E5, and wherein at least one of F1 - F5 is
or contains a
radioisotope; or
(g) stilbenes having the formula (7):
<IMG>
where W1 and W2 are, independently, alkyl, aryl, or OH; and wherein
G3 is OH and each of G1 - G2, G4 - G10 is independently selected from the
group of moieties
denoted by K; or
G2 and G4 are OH and each of G1, G3, G5 - G10 is independently selected from
the group of
moieties denoted by K; or
G3 and G8 are OH and each of G1- G3, G4- G7, G9- G10 is independently selected
from the
group of moieties denoted by K; or
G2 = G4 = G8 = OH and each of G1, G3, G5 - G7, G9 - G10 is independently
selected from the
group of moieties denoted by K;
and wherein in each case at least one of G1 - G10 is or contains a
radioisotope.
wherein in each case (a) - (g) K is selected from the group consisting of H;
alkyl; aryl;
18F; [18F]fluoroalkyl; [18F]fluoroaryl; 123I; [123I]iodoalkyl; [123I]iodoaryl;
124I; [124I]iodoalkyl;
[124I]iodoaryl; 125I; [125I]iodoalkyl; [125I]iodoaryl; -OR1, -SR1, or -NR1R2
(where R1 and R2
are independently H, alkyl, aryl, [11C]methyl, [18F]fluoroalkyl;
[18F]fluoroaryl;
[123I]iodoalkyl; [123I]iodoaryl; [124I]iodoalkyl; [124I]iodoaryl; [125I]
iodoalkyl; or
[125I]iodoaryl); -NO2; -CN; -S(=O)-R3 or -S(=O)2-R3 (where R3 is alkyl, aryl,
[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl,
[125I] iodoalkyl, [125I]iodoaryl), or -OR4, -NR4R5, (wherein R4 and R5 are
independently H,
alkyl, aryl, [11C]methyl, [18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl,
[123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl, [125I]iodoalkyl, or [125I]iodoaryl)); and -
OC(=O)-R6, -SC(=O)-
R6, or -NH-C(=O)-R6 (where R6 is alkyl, aryl, [11C]methyl, [18F]fluoroalkyl,
[18F]fluoroaryl,
[123I]iodoalkyl, [123I]iodoaryl, [124I]iodoalkyl, [124I]iodoaryl,
[125I]iodoalkyl, or [125I]iodoaryl).
--43--

8. A method as recited in claim 1, wherein the tracer comprises 4-[18F]fluoro-
3-
nitrophenol
9. A method as recited in claim 1, wherein the tracer comprises 3-[18F]fluoro-
4-
nitrophenol.
10. A method as recited in claim 1, further comprising administering to the
mammal at
least one environmental xenobiotic, before, during, or after administration of
the radiolabeled
tracer.
11. A method as recited in claim 10, wherein the xenobiotic comprises
cigarette smoke or
one or more components thereof.
12. A method of monitoring sulfotransferase activity in a mammal's brain, in
vivo,
comprising:
administering to a mammal a bolus of a radiolabeled tracer for a
sulfotransferase,
which tracer is capable of crossing the mammal's blood-brain barrier; and
generating radiographic data indicative of tracer uptake in the mammal's brain
by
scanning the brain using a radiographic technique, in vivo.
13. A method as recited in claim 12, wherein the mammal's brain is healthy.
14. A method as recited in claim 12 wherein the mammal is suffering from
Alzheimer's
disease, Parkinson's disease, non-Alzheimer's-type dementia, epilepsy, stroke,
brain tumor,
multiple sclerosis, or brain injury.
15. A method of monitoring sulfotransferase activity in a mammal, in vivo,
comprising:
administering to a mammal a bolus of a first radiolabeled tracer;
generating first radiographic data indicative of first tracer uptake in the
mammal by
scanning the mammal using a radiographic technique;
administering to the mammal a bolus of a second radiolabeled tracer;
generating second radiographic data indicative of second tracer uptake in the
mammal
by scanning the mammal using a radiographic technique; and
comparing the first radiographic data to the second radiographic data.
16. A method as recited in claim 15, further comprising using the first
radiographic data
to assess distribution or activity of a first sulfotransferase in the mammal;
using the second
radiographic data to assess distribution or activity of a second
sulfotransferase in the
--44--

mammal; and comparing the distribution or activity of the first
sulfotransferase to that of the
second sulfotransferase.
17. A method of monitoring sulfotransferase activity in a mammal, in vivo,
comprising:
administering to a mammal a bolus of a first radiolabeled tracer known to be a
substrate for a first sulfotransferase, but not a substrate for a second
sulfotransferase;
generating first radiographic data indicative of first tracer uptake in the
mammal by
scanning the mammal using a radiographic technique;
administering to the mammal a bolus of a second radiolabeled tracer;
generating radiographic data indicative of second tracer uptake in the mammal
by
scanning the mammal using a radiographic technique; and
comparing the first radiographic data to the second radiographic data.
18. A method as recited in claim 16, further comprising using the first
radiographic data
to assess distribution or activity of the first sulfotransferase in the
mammal; using the
radiographic data to assess distribution or activity of at least a second
sulfotransferase in the
mammal; and comparing the distribution or activity of the first
sulfotransferase to that of at
least the second sulfotransferase.
19. A method as recited in claim 17, wherein the second radiolabeled tracer is
known to
be a substrate for a second sulfotransferase, but not a substrate for the
first sulfotransferase.
20. A method as recited in claim 16, wherein the first radiolabeled tracer
comprises a
compound selected from Table 1, and the second radiolabeled tracer comprises a
compound
selected from Table 2.
21. A method as recited in claim 16, wherein the first radiolabeled tracer
comprises a
compound selected from Table 2, and the second radiolabeled tracer comprises a
compound
selected from Table 1.
22. A method as recited in claim 16, wherein the first radiolabeled tracer is
PIB and the
second radiolabeled tracer is an [18F]fluoronitrophenol.
23. A radiolabeled tracer for a sulfotransferase, comprising at least one
compound
selected from the group consisting of
(a) phenols having the formula (1)
--45--

<IMG>
where A1 is OH and each of A2 - A6 is independently selected from the group of
moieties
denoted by "K" (defined below), provided that at least one of A2 - A6 is or
contains a
radioisotope; or A1 and A3 are both OH and each of A2, A4 - A6 is
independently selected
from the group of moieties denoted by K, provided that at least one of A2, A4 -
A6 is or
contains a radioisotope;
(b) naphthols having the formula (2)
<IMG>
where B1 is OH and each of B2 - B8 is independently selected from the group of
moieties
denoted by K, provided that at least one of B2 - B8 is or contains a
radioisotope; or B2 is OH
and each of B1, B3 - B8 is independently selected from the group of moieties
denoted by K,
provided that at least one of B1, B3 - B8 is or contains a radioisotope; or B1
and B3 are each
OH and each of B2, B4 - B8 is independently selected from the group of
moieties denoted by
K, provided that at least one of B4 - B8 is or contains a radioisotope;
(c) coumarins having the formula (3)
<IMG>
--46--

where X and Y are, independently, O, S, or N-R1 (wherein R1 is H, alkyl, aryl,
[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl,]
[125I]iodoalkyl, or [125I]iodoaryl); and wherein
C3 is OH and each of C1 - C2, C4 - C6 is independently selected from the group
of moieties
denoted by K; or
C4 is OH and each of C1 - C3, C5 - C6 is independently selected from the group
of moieties
denoted by K; or
C5 is OH and each of C1 - C4, C6 is independently selected from the group of
moieties
denoted by K; or
C6 is OH and each of C1 - C5 is independently selected from the group of
moieties denoted by
K; or
C2 and C3 = OH and each of C1, C4 - C6 is independently selected from the
group of moieties
denoted by K; or
C2 and C4 = OH and each of C1, C3, C5 - C6 is independently selected from the
group of
moieties denoted by K; or
C2 and C5 = OH and each of C1, C3 - C4, C6 is independently selected from the
group of
moieties denoted by K; or
C2 and C6 = OH and each of C1, C3 - C5 is independently selected from the
group of moieties
denoted by K; or
C3 and C5 = OH and each of C1 - C2, C4, C6 is independently selected from the
group of
moieties denoted by K; or
C4 and C6 = OH and each of C1 - C3, C5 is independently selected from the
group of moieties
denoted by K; or
C2 = C3 = C5 = OH and each of C1, C4, C6 is independently selected from the
group of
moieties denoted by K; or
C2, C4 and C6 = OH and each of C1, C3, C5 is independently selected from the
group of
moieties denoted by K;
wherein in each case at least one of C1 - C6, X, or Y is or contains a
radioisotope;
(d) flavones having the formula (4)
<IMG>
--47--

where X and Y are, independently, O, S, or N-R1 (wherein R1 is H, alkyl, aryl,
[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl,]
[125I]iodoalkyl, or [125I]iodoaryl); and wherein
D3 is OH and each of D1 - D2, D4 - D6 is independently selected from the group
of moieties
denoted by K; or
D4 is OH and each of D1 - D3, D5 - D6 is independently selected from the group
of moieties
denoted by K; or
D5 is OH and each of D1 - D4, D6 is independently selected from the group of
moieties
denoted by K; or
D6 is OH and each of D1 - D5 is independently selected from the group of
moieties denoted
by K; or
D2 and D3 are OH and each of D1, D4 - D6 is independently selected from the
group of
moieties denoted by K; or
D2 and D4 are OH and each of D1, D3, D5 - D6 is independently selected from
the group of
moieties denoted by K; or
D2 and D5 are OH and each of D1, D3 - D4, D6 is independently selected from
the group of
moieties denoted by K; or
D2 and D6 are OH and each of D1, D3 - D5 is independently selected from the
group of
moieties denoted by K; or
D3 and D5 are OH and each of D1 - D2, D4, D6 is independently selected from
the group of
moieties denoted by K; or
D4 and D6 are OH and each of D1 - D3, D5 is independently selected from the
group of
moieties denoted by K; or
D2, D3 and D5 are OH, and D1, D4, D6 is independently selected from the group
of moieties
denoted by K; or
D2, D4 and D6 are OH, and D1, D3, D5 is independently selected from the group
of moieties
denoted by K;
wherein in each case at least one of D1 - D6, X, or Y is or contains a
radioisotope;
and wherein K is selected from the group consisting of H; alkyl; aryl; 18F;
[18F]fluoroalkyl;
[18F]fluoroaryl; 123I; [123I]iodoalkyl; [123I]iodoaryl; 124I; [124I]iodoalkyl;
[124I]iodoaryl; 125I;
[125I]iodoalkyl; [125I]iodoaryl; -OR1, -SR1, or -NR1R2 (where R1 and R2 are
independently H,
alkyl, aryl, [11C]methyl, [18F]fluoroalkyl; [18F]fluoroaryl; [123I]iodoalkyl;
[123I]iodoaryl;
[124I]iodoalkyl; [124I]iodoaryl; [125I]iodoalkyl; or [125I]iodoaryl); -NO2; -
CN; -S(=O)-R3 or -
S(=O)2-R3 (where R3 is alkyl, aryl, [11C]methyl, [18F]fluoroalkyl,
[18F]fluoroaryl,
[123I]iodoalkyl, [123I]iodoaryl, [124I]iodoalkyl, [124I]iodoaryl,
[125I]iodoalkyl, [125I]iodoaryl), or
-OR4, -NR4R5, (wherein R4 and R5 are independently H, alkyl, aryl,
[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl,
[125I]iodoalkyl, or [125I]iodoaryl)); and -OC(=O)-R6, -SC(=O)-R6, or -NH-C(=O)-
R6 (where
--48--

R6 is alkyl, aryl, [11C]methyl, [18F]fluoroalkyl, [18F]fluoroaryl,
[123I]iodoalkyl, [123I]iodoaryl,
[124I]iodoalkyl, [124I]iodoaryl, [125I]iodoalkyl, or [125I]iodoaryl).
--49--

Description

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 IN VIVO IMAGING OF SULFOTRANSFERASES
ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT
[0001] This application was made with government support under Grant No. DE-
FC02-
02ER63420 (J. R. Barrio), awarded by the United States Department of Energy.
The
Government has certain rights in the invention.
FIELD OF THE INVENTION
[0002] The present invention generally relates to radiolabeled molecular
probes (tracers)
for monitoring sulfotransferase distribution and activity in vivo.
BACKGROUND OF THE INVENTION
[0003] Sulfotransferases ("SULTs") are a class of enzymes that catalyze
sulfonation of
compounds that carry either a hydroxyl group or an amino group, and play an
important role
in metabolism of xenobiotics, drugs and many endogenous compounds. They have a
wide
distribution in the body and act as major metabolic/detoxification systems
(Phase II metabolic
enzymes) in regulating homeostasis of the body. They are highly expressed in
tissues that are
exposed to foreign compound: the lungs and respiratory tract (including the
nasal cavity), the
gastrointestinal tract, and the liver. In the majority of cases, addition of
sulfonate moiety to
the structure increases its solubility, because sulfates are fully ionized at
physiological pH,
and decreases biological activity. Yet these enzymes are also capable of
bioactivating
procarcinogens to reactive electrophiles. (Falany, 1997; Gamage et al., 2006)
The universal
sulfonate donor for the sulfonations catalyzed by sulfotransferases is 3'-
phospho-adenosyl-
5'-phosphosulfate (PAPS). (Robbins and Lippman, 1956)
[0004] A variety of drugs and natural products are either substrates or
inhibitors of these
compounds. For example, several natural compounds that exhibit antioxidant and
anticancer
activity, such as curcumin from curry powder and epigallocatechins from green
tea, are
potent inhibitors of phenolic sulfotransferases.
[0005] The protective role of these sulfotransferase inhibitors may be better
understood if
we take into account the involvement of sulfotransferases in the activation of
several pro-
carcinogenic compounds to fully activated carcinogens. This happens when
hydroxyl groups
in allylic or benzylic alcohols, or in hydroxylamines formed from aromatic
amines, get
sulfonated. The resulting sulfates are unstable and readily decompose to
inorganic sulfate
and highly reactive electrophilic carbonium or nitrenium cations. These
species can then
attack highly nucleophilic DNA and covalently bind to it, which may lead to
mutagenesis and
carcinogenesis.
-- 1 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [0006] Similarly, several drugs or their metabolites having phenolic
hydroxyl groups are
also metabolized predominantly through sulfonation. Examples include the
cancer drugs
raloxifene and tamoxifen:
l40 S 0--\_N/
0 ~ 0H I I~ =
Nzz
01.1
Raloxifene trans 4-OH Tamoxifen
[0007] Sulfotransferases can be divided into two large groups: the cytosolic
SULTs and
the membrane-associated SULTs, which are localized in the Golgi apparatus.
Cytosolic
SULTs catalyze the sulfonation of xenobiotics, hormones, monoamine
neurotransmitters, and
drugs. Orally administered xenobiotics and drugs are to a large extent
sulfonated in the
intestines and in the liver, and excreted either via urine or via bile.
Membrane-associated
SULTs catalyze the sulfonation of proteins and carbohydrates for processes
such as cellular
signaling and modulation of receptor binding, such as glycosaminoglycans,
glycoproteins,
etc. Recent studies have implicated the SULTs in a number of disease states,
including entry
of the herpes virus, (Xu ea al., 2006) entry of HIV (Seibert et al. 2002),
chronic inflammation
(van Zante and Rosen, 2003), and cancer (Suzuki et al., 2003).
[0008] Five distinctive cytosolic sulfotransferase gene families have been
identified in
mammals (SULT1 - SULT5), of which only SULT1, SULT2 and SULT4 have been
identified in humans. (Hempel, 2005) Ten distinctive members of these 3
families were
identified: SULT1: Al, A2, A3, 131, Cl, C2, El; SULT2: Al and Bl; and SULT4A1.
[0009] SULTIA sulfotransferases are the most abundant and widespread among the
10
members and they differ based on their metabolic preference for different
substrates (phenol
sulfotransferase SULTIAI, monoamine sulfotransferase SULTIA3).
[0010] The major role of sulfonation in the body is metabolism and
detoxification of
xeno- and endobiotics via conjugation with sulfonate moiety, which makes the
compounds
more soluble at physiological pH and easier to excrete. In addition to
sulfoconjugation of
drugs and xenobiotics having hydroxyl groups (or metabolites hydroxylated by
Phase I
metabolic enzymes), glucuronidation also may contribute in metabolism and
excretion of
these compounds. Sulfonation and glucuronidation are complementary conjugation
processes
and take place in different cellular compartments: sulfonation in the cytosol
and
glucuronidation in the endoplasmic reticulum. Sulfonation is considered a high
affinity, low
capacity pathway, whereas glucuronidation is considered to be a low affinity,
high capacity
pathway. (Burchell and Coughtrie, 1997) In general these two enzyme systems
also show
-- 2 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 differences in tissue localization, with major SULT expression occurring in
organs facing
high exposure to foreign chemicals (e.g., lungs, intestines) and, at the same
time, relatively
low UDP-glucuronosyltransferase activity in the same organs. (Pacifici et al.,
1998)
[0011] In addition to metabolism and excretion, sulfonation also plays a
strong regulatory
role for several classes of endogenous substrates, including estrone,
cholesterol, dopamine,
bile acid salts, testosterone, and neuroendocrine peptide cholecystokinin
(CCK). For
example, in normal human plasma, 99% of total dopamine, 78% of total
noradrenaline, and
67% of total adrenaline is present in inactive sulfonated form. (Eisenhofer et
al., 1999)
Similarly, the level of the inactive sulfonated form of the hydroxysteroid
hormone
dehydroepiandrosterone (DHEA) in plasma is 100-fold higher than the level of
unsulfonated
DHEA. (Falany, 1997)
[0012] Sulfonation can also increase activity of endogenous molecules, as in
the case of
the neuroendocrine peptide cholecystokinin (CCK), which exhibits biological
activity when
in sulfated form. (Vargas et al., 1994)
[0013] A variety of xenobiotics are substrates for different SULT1 enzymes in
the
intestines and liver. Examples are (-)-salbutamol, 7-OH-flavone, paracetamol,
and (-)-
apomorphine. Some natural products and chemicals are potent inhibitors of
SULTIAI and
SULTIA3 activities, including 2,6-dichloro-4-nitrophenol (DCNP), curcumin, and
quercitin,
among others. (Pacifici, 2005)
[0014] The human brain displays a moderate level of SULT1 activity.
Sulfonation
activity for dopamine (SULTIA3) and for p-nitrophenol (SULTIAI) was measured
in 17
brain regions of 6 brains from subjects of age 55-74 years. There were
considerable regional
differences in both SULT activities, with the values for neocortical regions
(frontal, parietal,
temporal) significantly higher than for the subcortical regions and
cerebellum. SULTIAI
activity observed in the frontal cortex was 4.7 times higher than that
observed in the
thalamus, and SULTIA3 activity was 4.0 times higher in the frontal cortex than
in the
thalamus. (Young and al., 1984) The authors also assessed the extent of SULT
activity loss
as a function of post-lobectomy delay in a study on brain tissue from 5
lobectomy patients.
Loss of activity was 20% in the post-surgery brain samples 8 hours after
tissue removal.
SULTIEI has been detected in human brain tissue (Miki, et al., 2002)
[0015] The immunohistochemical detection of phenol sulfotransferase-containing
neurons in tissue samples from 4 normal brains obtained 6-12 hours after death
revealed that
the immunostaining was localized to the cytosol of specific neuronal
populations in each
region analyzed, i.e., the hippocampus, thalamus, striatum, and medulla. (The
antibody used
was cross-reacting with SULTIIAI and SULTIIA3.) However, no other areas of
cortex
(frontal, parietal, or occipital) were analyzed, which prevents us from making
any significant
correlations with the study of Young et al.
-- 3 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [0016] R(-)-apomorphine, a drug used for treatment of Parkinson's disease
has been
found to be sulfonated by the brain SULTIA enzymes. As in the case of liver
and intestinal
sulfonation of this drug, it can be blocked with quercitin with IC50 value of
16 2.3 nM.
(Vietri et al., 2002b).
[0017] In addition to the SULT1 family, the SULT4 family has been discovered
and was
found to be localized in brain tissues only. (Liyou et al., 2003) Although the
authors were
unable to identify the substrates for this enzyme, we can conclude, based on
very high inter-
species preservation of the enzyme structure, that it is involved in an
important process.
The Role of Sulfotransferases in Disease
[00181 The interaction between sulfotransferases and carcinogens, i.e.
activation and
inactivation of carcinogens by sulfotransferases, has been extensively
studied. (Glatt, 2005).
A majority of the pro-carcinogens are aromatic compounds, which can be easily
functionalized in such manner that they contain either a benzylic or allylic
alcohol or an
aromatic hydroxylamine structural unit. The hydroxy group is readily
sulfonated by the
sulfotransferases, yielding activated sulfuric acid esters of benzylic and
allylic alcohols, and
aromatic hydroxylamines, which readily lose the sulfate moiety to form
resonance-stabilized
carbonium or nitrenium ions. These reactive electrophilic species then react
with
nucleophilic sites on DNA, leading to mutagenicity and carcinogenicity.
[0019] The polymorphism of the sulfotransferase SULTIA1 gene leads to Arg-to-
His
substitution at the codon 213, which leads to lower activity and thermal
stability of the
enzyme. Several studies have tried to link the decreased activity of SULTIAI
to higher risk
for several types of cancers, including gastric cancers among males who drink
and smoke
(Boccia et al. 2005), head and neck cancer amongst older people who are
alcohol and low
fruit consumers (Boccia et al., 2006), esophageal cancer in men (Wu et al.,
2003), lung
cancer in current smokers and current heavy smokers (Wang et al., 2001), and
breast cancer
(Shatalova et al., 2005).
[0020] The SULTIAI and SULTIA3 sulfotransferases were reported to have
increased
activity in the thyroid glands of autoimmune thyroid disease patients, and
SULTIAI activity
was elevated in nodular goiter patients when compared to healthy controls.
(Ebmeier and
Anderson, 2004)
[00211 Neurodegenerative diseases are another class of diseases with
sulfotransferase
involvement. A study of SULTIA3 activity performed on brain tissue samples
from 7
Parkinson's disease patients and 8 controls suggests that SULTIA3 activity was
decreased in
all neocortical areas of PD patients (20 - 39% of controls) when compared with
controls, but
was increased in the caudate nucleus area with pathology in PD (174-203% of
controls).
(Baran and Jellinger, 1992)
-- 4 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [0022] Although there are no direct reports on the fate of sulfotransferases
in Alzheimer's
disease (AD), the most common neurodegenerative disease, there is a wealth of
evidence that
the neuropathological fibrillar deposits found in AD, namely 0-amyloid plaques
and
neurofibrillary tangles, are all associated with heparan sulfate proteoglycans
(van Horssen et
al., 2003; Verbeek et al., 1999), which may be aiding in fibrillogenesis and
also have some
anti-protease activity which would protect the amyloid aggregates from
degradation the same
way as heparan sulfate proteoglycans protect basic fibroblast growth factor
from proteolysis
when bound to it. (Saksela et al., 1988)
[0023] In a way analogous to Parkinson's disease, where the highest SULTIA3
activity is
observed in areas having the strongest neurodegeneration in the dopaminergic
brain system,
we predict that the significant changes of activity and/or expression of SULT1
enzymes in
Alzheimer's disease will reflect the global cortical and subcortical
distribution of
neurodegenerative processes (i.e., neuronal loss, synaptic loss, and formation
of
neurofibrillary tangles and 0 -amyloid plaques.
Alzheimer's Disease
[0024] Alzheimer's disease is a progressive neurodegenerative disease that
affects
approximately 20-40% of the population over 80 years of age, the fastest
growing age group
in the United States and other post-industrial countries. Common features in
the brains of
patients with Alzheimer's disease include extensive loss of neurons from the
vulnerable
neuronal population and the presence of neuropathological deposits, including
(3-amyloid
senile plaques (SP) and neurofibrillary tangles (NFT)s. As the disease
worsens, the deposits
spread throughout the brain in a predictable pattern starting from the medial
temporal lobe
and progressing gradually to the rest of the cortex. (Braak and Braak, 1991)
Related
pathologies are seen in other forms of dementia (e.g. Frontotemporal Dementia)
and in Down
Syndrome.
[0025] Since the initial deposits occur much earlier than the symptoms of the
disease,
early in vivo imaging of these deposits has tremendous diagnostic value. A
method using
"[18F]FDDNP" (2-(1-{6-[(2-[ 18F]fluoroethyl)(methyl)amino]-2-
naphthyl}ethylidene)
malononitrile), a [F-18]fluorine labeled probe, has been developed for in vivo
detection of
neuropathological deposits in Alzheimer's disease with positron emission
tomography (PET).
It has been used to determine in vivo levels of the pathological deposits
present in brains of
Alzheimer's disease patients, and consistently shows higher levels of
[18F]FDDNP binding in
the brain areas with known pathology when compared with the levels determined
in the same
areas in the brains of cognitively normal, age-matched subjects (Shoghi-Jadid
et al., 2002;
Kepe et al., 2004). In vitro results demonstrate the capacity of [18F]FDDNP to
bind to both
major types of neuropathological deposits found in Alzheimer's disease:
extracellular 0-
amyloid senile plaques (SP) and intracellular neurofibrillary tangles (NFT).
(Agdeppa et al.,
-- 5 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 2003 a) This binding can be selective blocked by naproxen, a non-steroidal
inflammatory
drug. (Agdeppa et al., 2003b)
100261 Two other types of [11C] carbon-radiolabeled compounds suitable for PET
have
been developed and are reported to have specific binding to 0-amyloid
fibrillary aggregates
and used for brain PET imaging in Alzheimer's disease. The first is a
benzothiazole
derivative: 2-[(4'-[11C]methylamino)phenyl]-6-hydroxybenzothiazole ("[11C]6-OH-
BTA-1"
or "PIB"), which has been used to study Alzheimer's disease patients and
controls with PET
(Klunk et al., 2004). The second is a stilbene derivative: 4-([C-
1l]methylamino)-4'-
hydroxystilbene, which has been developed for PET studies and used in a small
study with 3
Alzheimer's disease patients and 3 controls. (Verhoef et al., 2004). The
results are
comparable to the results obtained with [11C]6-OH-BTA in the same subjects. As
both [C-
11]6-OH-BTA and 4-([11C]methylamino)-4' -hydroxystilbene are phenolic
compounds and
therefore sulfotransferase substrates, it is reasonable to assume that at
least part of the
observed signal results from the sulfonation of both probes in the brain and
retention of the
resulting sulfates. Indeed, [11C]6-OH-BTA has been shown to be sulfonated in
the rat brain
in vivo. (Mathis et al., 2004)
[0027] Although it is recognized that sulfotransferases play an important role
in health
and disease, no method currently exists for measuring sulfotransferases in
vivo, and much
remains to be learned about their distribution in the body and their role in
the evolution of
diseases such as Alzheimer's Disease, cancer, and lung disease related to
smoking. An urgent
need exists for a method of monitoring the distribution and activity of SULTs
in vivo, and for
assessing the effect of therapeutic interventions aimed at this class of
enzymes.
SUMMARY OF THE INVENTION
[0028] It has now been discovered that certain radiolabeled compounds are well-
suited
for use as molecular imaging probes (sometimes referred to as "radiographic
tracers,"
"radiolabeled tracers," or simply, "tracers") for sulfotransferases in vivo.
Included are
substituted phenols, naphthols, coumarins and, flavones, radiolabeled with
18F11231, 1241, 1251,
or 11C, as more fully presented in Table I below. These compounds comprise a
first aspect of
the invention. A method of making radiolabeled tracers is also provided.
Additional tracers
for SULTs are presented in Table 2 and include substituted benzothiazoles and
similar fused
ring compounds, imidazopyridines, and stilbenes, radiolabeled with 18F 1231,
1241 1251> or 11C.
[0029] In another aspect of the invention, a method of assessing SULT
distribution and/or
activity in a human or non-human mammal; in vivo, is provided, and comprises
administering
to the mammal a bolus of at least one tracer listed in Table 1, Table 2, or
each of Tables 1 and
2; generating dynamic imaging indicative of tracer uptake in the mammal by
scanning the
mammal using a radiographic technique; and using the generated radiographic
data to assess
SULT distribution and/or activity in the mammal. One or more regions of
interest, e.g., the
-- 6 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 brain, lungs, heart, liver, etc. --or even the mammal's entire body-- can be
scanned and SULT
activity therein can be monitored dynamically. This aspect of the invention
can also be used
to assess the effect of various therapeutic interventions aimed at reducing
inflammation and
other conditions in which SULTs are implicated; to map SULT expression in
vivo; and to
monitor the effect of exposure to xenobiotics (e.g. in the lungs and
respiratory tract, and in
the gastrointestinal tract).
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Various aspects, features, and advantages of the invention will become
better
understood when considered in conjunction with the following detailed
description and by
making reference to the appended drawings, wherein:
[0031] FIG. 1 is a table listing 12 different unlabeled, fused ring compounds
(nos. 1-12)
of interest for the invention, showing the effect of ring substituents on
sulfotransferase
(SULT 1 A 1 and SULT 1 E 1) activity (Km, Vmax, Vmax/Km);
[0032] FIG. 2 is a table listing 12 different unlabeled, fused ring compounds
(nos. 1-12)
of interest for the invention, showing the effect of ring substituents on
sulfotransferase
(SULT 1 A3 and SULT2A 1) activity (Km, Vmax, Vmax/Km);
[0033] FIG. 3 is a table listing 13 different unlabeled, fused ring compounds
(nos. 13-25)
of interest for the invention, showing the effect of ring substituents on
sulfotransferase
(SULT I A I and SULTIEI) activity (Km, Vmax, Vmax/Km);
[0034] FIG. 4 is a table listing 13 different unlabeled, fused ring compounds
(nos. 13-25)
of interest for the invention, showing the effect of ring substituents on
sulfotransferase
(SULTIA3 and SULT2A1) activity (Km, Vm, Vmax/Km);
[0035] FIG. 5 is a pair of microPET images of sulfotransferase (SULTIEI)
expression in
rats, generated in vivo using the radiolabeled substrate 2-(4'-([11C]-
methylamino)phenyl)-6-
hydroxybenzothiazole as a tracer, according to the invention;
[0036] FIG. 6 is a pair of in vivo microPET images of sulfotransferase
(SULTIEI)
expression in two adult male humans, one a non-smoker and the other a smoker,
generated
using the radiolabeled substrate 2-(4'-([ C]-methylamino)phenyl)-6-
hydroxybenzothiazole as
a tracer, according to the invention; and
[0037] FIG. 7 is a set of four microPET images of sulfotransferase activity
and inhibition
in a pair of Sprague-Dawley rats, one healthy and one suffering from renal
hypertension,
chronic progressive nephropathy, and lung inflammation, generated in vivo
using the
substrate 4-[18F]-fluoro-3-nitrophenol as a tracer and 2,6-dichloro-4-
nitrophenol as an
inhibitor, according to the invention.
DETAILED DESCRIPTION
-- 7 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [0038] The present invention provides radiolabeled tracers that are
substrates or inhibitors
of sulfotransferases (SULTs), a method of making the tracers, and methods for
using the
tracers in vivo to assess sulfotransferase distribution and activity in health
and disease, as well
as the effect of pharmacological agents and xenobiotics that inhibit, promote,
or otherwise act
on the enzymes when administered to humans and other mammals. In one aspect of
the
invention, an in vivo method of monitoring one or more SULTs in a mammal is
provided. In
one embodiment, a bolus of a radiolabeled tracer that functions as a substrate
or inhibitor of
one or more SULT is administered to a mammal; radiographic data indicative of
tracer uptake
is generated by scanning the mammal using a radiographic technique, e.g.,
autoradiography,
scintillation counting, PET (including micro-PET), SPECT, etc.; and the
generated
radiographic data is used to probe or assess SULT distribution or activity in
the mammal. In
a variation of this embodiment, a dynamic study is performed to establish the
time-dependent
distribution of the tracer. The invention is used to monitor SULT distribution
and function in
humans, non-human primates, dogs, rodents, and other mammals, including those
having
normal SULT genes and those having defective SULT genes. The use of wild type,
transgenic, and/or knockout rodents can be particularly useful in certain
research programs.
[0039] Using this procedure we establish SULT localization based on the
functional
activity of the radiolabeled substrate used: e.g., If the substrate is
specific for SULT 1A1. In
this sense "activity" can be viewed as the ability of the specific CULT enzyme
to transform a
radiolabeled substrate into its sulfate resulting in tissue retention. This
specific tissue
retention is related to the localization and activity of the SULT enzyme and
can be measured
with radiographic procedures (e.g., PET).
[0040] As used herein, the term "radiolabeled" means that the tracer is
isotopically
enriched with at least one radioisotope. The tracers can be divided into
several categories.
Table I presents substituted phenols, naphthols, coumarins, and flavones, each
radiolabeled
with 18F, 1231, 124I1125I, or "C. Table 2 presents substituted benzothiazoles,
structurally
related fused ring compounds, imidazopyridines, and stilbenes, each
radiolabeled with 18F,
1231, 1241, 125I, or 11 C .
[0041] Table 1: Selected Radiolabeled Tracers for SULTs
[0042] A. PHENOLS (1)
A,
A6 A2
A5 A3
A4 I
--8--

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 where Al is OH and each of A2 - A6 is independently selected from the group
of moieties
denoted by "K" (defined below), provided that at least one of A2 - A6 is or
contains a
radioisotope; or Al and A3 are both OH and each of A2, A4 - A6 is
independently selected
from the group of moieties denoted by K, provided that at least one of A2, A4 -
A6 is or
contains a radioisotope.
B. NAPHTHOLS (2)
B8 Bi
67 ~ ~ B2
B6 B3
B5 B4 2
where B1 is OH and each of B2 - B8 is independently selected from the group of
moieties
denoted by K, provided that at least one of B2 - B8 is or contains a
radioisotope; or B2 is OH
and each of B1, B3 - B8 is independently selected from the group of moieties
denoted by K,
provided that at least one of B1, B3 - B8 is or contains a radioisotope; or B1
and B3 are each
OH and each of B2, B4 - B8 is independently selected from the group of
moieties denoted by
K, provided that at least one of B4 - B8 is or contains a radioisotope.
C. COUMARINS (3)
C6
C5 / X Y
C4 ~ Ci
C3 C2 3
where X and Y are, independently, 0, S, or N-R' (wherein R1 is H, alkyl, aryl,
[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, ['23I]iodoalkyl, [123I]iodoaryl,
['24I]iodoalkyl, ['24I]iodoaryl,]
[125I]iodoalkyl, or [125I]iodoaryl); and wherein
C3 is OH and each of C1- C2, C4 - C6 is independently selected from the group
of moieties
denoted by K; or
C4 is OH and each of C1- C3, C5 - C6 is independently selected from the group
of moieties
denoted by K; or
-- 9 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 C5 is OH and each of C1 - C4, C6 is independently selected from the group of
moieties
denoted by K; or
C6 is OH and each of C1- C5 is independently selected from the group of
moieties denoted by
K; or
C2 and C3 = OH and each of C1, C4 - C6 is independently selected from the
group of moieties
denoted by K; or
C2 and C4 = OH and each of C1, C3, C5 - C6 is independently selected from the
group of
moieties denoted by K; or
C2 and C5 = OH and each of C1, C3 - C4, C6 is independently selected from the
group of
moieties denoted by K; or
C2 and C6 = OH and each of C1, C3 - C5 is independently selected from the
group of moieties
denoted by K; or
C3 and C5 = OH and each of C1 - C2, C4, C6 is independently selected from the
group of
moieties denoted by K; or
C4 and C6 = OH and each of C1 - C3, C5 is independently selected from the
group of moieties
denoted by K; or
C2 = C3 = C5 = OH and each of C1, C4, C6 is independently selected from the
group of
moieties denoted by K; or
C2, C4 and C6 = OH and each of C1, C3, C5 is independently selected from the
group of
moieties denoted by K;
and wherein in each case at least one of C1 - C6, X, or Y is or contains a
radioisotope.
D. FLAVONES (4)
DD5 30 D3 Y 4
where X and Y are, independently, 0, S, or N-R' (wherein R1 is H, alkyl, aryl,
C] methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [123I]iodoalkyl, ['23I]iodoaryl,
['241]iodoalkyl, ['24I]iodoaryl,]
[1251]iodoalkyl, or ['251]iodoaryl); and wherein
D3 is OH and each of D1 - D2, D4 - D6 is independently selected from the group
of moieties
denoted by K; or
D4 is OH and each of D1 - D3, D5 - D6 is independently selected from the group
of moieties
denoted by K; or
-- 10 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
I D5 is OH and each of D1 - D4, D6 is independently selected from the group of
moieties
denoted by K; or
D6 is OH and each of D1 - D5 is independently selected from the group of
moieties denoted
by K; or
D2 and D3 are OH and each of DI, D4 - D6 is independently selected from the
group of
moieties denoted by K; or
D2 and D4 are OH and each of DI, D3, D5 - D6 is independently selected from
the group of
moieties denoted by K; or
D2 and D5 are OH and each of DI, D3 - D4, D6 is independently selected from
the group of
moieties denoted by K; or
D2 and D6 are OH and each of DI, D3 - D5 is independently selected from the
group of
moieties denoted by K; or
D3 and D5 are OH and each of D1 - D2, D4, D6 is independently selected from
the group of
moieties denoted by K; or
D4 and D6 are OH and each of D1 - D3, D5 is independently selected from the
group of
moieties denoted by K; or
D2, D3 and D5 are OH, and DI, D4, D6 is independently selected from the group
of moieties
denoted by K; or
D2, D4 and D6 are OH, and DI, D3, D5 is independently selected from the group
of moieties
denoted by K;
and wherein in each case at least one of D1 - D6, X, or Y is or contains a
radioisotope.
[0043] Table 2: Additional Radiolabeled Tracers for SULTs
E. BENZOTHIAZOLES AND STRUCTURALLY RELATED FUSED RING
COMPOUNDS (5)
E5
E4 Z
I Ei
E
3 W
E2 5
where Z is 0, S, N-R' (wherein R' is H, alkyl, aryl, [11 C]methyl,
[18F]fluoroalkyl,
[18F]fluoroaryl, [123I]iodoalkyl, [123I]iodoaryl, ['24I]iodoalkyl,
['24I]iodoaryl,] [125I]iodoalkyl,
or [125I]iodoaryl), CH2, or CH=CH; and W is N or CH; and wherein
-- 11 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 E2 is OH and each of E1, E3 - E5 is independently selected from the group of
moieties
denoted by K; or
E3 is OH and each of E1- E2, E4 - E5 is independently selected from the group
of moieties
denoted by K; or
E4 is OH and each of E1- E3, E5 is independently selected from the group of
moieties denoted
by K; or
E5 is OH and each of E1- E4 is independently selected from the group of
moieties denoted by
K; or
E2 and E4 are OH and each of E1- E4 is independently selected from the group
of moieties
denoted by K; or
E3 and E5 are OH and each of E1, E2, E4, is independently selected from the
group of moieties
denoted by K;
and wherein in each case at least one of E1- E5 or Z is or contains a
radioisotope.
Itis noted that, if Z is S and W is N, the compounds are benzothiazoles; if Z
is 0 and
W is N, the compounds are benzooxazoles; and if Z is CH2 and W is N, the
compounds are
benzoazoles.
A subset of such fused ring compounds, in which E1 is a substituted aryl
group, has
the formula 5a:
E5 E4 Z / \ R'
N\
E3 W R..
E2 5a
where Z is 0, S, N-R1 (wherein R1 is H, alkyl, aryl, [11C]methyl,
[i8F]fluoroalkyl,
[18F]fluoroaryl, [1231]iodoalkyl, [123I]iodoaryl, [124I]iodoalkyl,
[124I]iodoaryl,] [125I]iodoalkyl,
or [125I]iodoaryl), CH2, or CH=CH; W is N or CH; and I' is H, alkyl, aryl,
[11C]methyl, 18F,
[18F]fluoroalkyl, [18F]fluoroaryl, 123I, [123I]iodoalkyl, [123I]iodoaryl,
1241, [124I]iodoalkyl,
[124I]iodoaryl,] 1251, [125I]iodoalkyl, or [1251]iodoaryl);
and wherein E2 is OH and each of E3 - E5 is independently selected from the
group of
moieties denoted by K; or
E3 is OH and each of E2, E4 - E5 is independently selected from the group of
moieties
denoted by K; or
E4 is OH and each of E2 - E3, E5 is independently selected from the group of
moieties denoted
by K; or
-- 12 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
I E5 is OH and each of E2 - E4 is independently selected from the group of
moieties denoted by
K; or
E2 and E4 are OH and each of E3, E5 is independently selected from the group
of moieties
denoted by K; or
E3 and E5 are OH and each of E2, E4 is independently selected from the group
of moieties
denoted by K;
wherein in each case at least one of E1- E5, I', or Z is or contains a
radioisotope.
F. Structurally related IMIDAZOPYRIDINES (6) having the same combinations of
substituents as the fused ring compounds 5 (i.e., F1 - F5 are the same as E1 -
E5), wherein at
least one of F1 - F5 is or contains a radioisotope.
F5
F4 iN
F,
N
F3
F2 6.
G. STILBENES (77)
Ge
G8 G10
W, G, G
G7 2
G6 w2 I
G5 G3
G4 7
where W1 and W2 are, independently, alkyl, aryl, or OH; and wherein
G3 is OH and each of G1- G2, G4- G10 is independently selected from the group
of moieties
denoted by K; or
G2 and G4 are OH and each of G1, G3, G5- G10 is independently selected from
the group of
moieties denoted by K; or
G3 and G8 are OH and each of G1- G3, G4 - G7, G9 - G10 is independently
selected from the
group of moieties denoted by K; or
--13--

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 G2 = G4 = G8 = OH and each of G1, G3, G5 - G7, G9 - G10 is independently
selected from the
group of moieties denoted by K;
and wherein in each case at least one of G1 - G10 is or contains a
radioisotope.
[0044] Also included are the CIS-STILBENES, in which W1 is cis to W2.
[0045] As used herein, "K" denotes the following chemical moieties: H; alkyl;
aryl; 18F;
[18F]fluoroalkyl; [18F]fluoroaryl; 1231; [123I]iodoalkyl; [1231]iodoaryl;
1241; [124I]iodoalkyl;
[1241]iodoaryl; 1251; [1251]iodoalkyl; [1251]iodoaryl; -OR1, -SR1, or NR1R2
(where R' and R2
are independently H, alkyl, aryl, ["C]methyl, [18F]fluoroalkyl;
[18F]fluoroaryl;
[1231]iodoalkyl; [1231] iodoaryl; [1241]iodoalkyl; [124I]iodoaryl; [125
I]iodoalkyl; or
[1251]iodoaryl); -NO2; -CN; -S(=O)-R3 or -S(=O)2-R3 (where R3 is alkyl, aryl,
[11C]methyl,
[18F]fluoroalkyl, [18F]fluoroaryl, [1231]iodoalkyl, [1231]iodoaryl,
[1241]iodoalkyl, [124I]iodoaryl,
[125I]iodoalkyl, [125I]iodoaryl), or -OR4, -NR4R5, (wherein R4 and R5 are
independently H,
alkyl, aryl, 11C meth 1 [18F]fluoroalkyl, [ 18 F]fluoroaryl, [1231]iodoalkyl,
[121I]iodoaryl,
[1241] iodoalkyl, [I24I]iodoaryl, [125I]iodoalkyl, or 125I iodo 1 OC(=O)-R6
SC(=O)-R6
or -NH-C(=O)-R6 (where R6 is alkyl, aryl, [11C]methyl, [18F]fluoroalkyl,
[18F]fluoroaryl,
[1231] iodoalkyl, [123I]iodoaryl, [1241] iodoalkyl, [124I]iodoaryl,
[125I]iodoalkyl, or [1251]iodoaryl).
[0046] In one embodiment of the invention, the general protocol for preparing
the
radiolabeled tracers recited in Tables 1 and 2 includes the following steps:
(1) preparation of
the radiolabeling agent; (2) reaction with a precursor molecule
(radiolabeling); (3) work-up of
the reaction mixture; (4) HPLC separation; (5) isolation and identification of
the radiolabeled
compound; and (6) preparation of the final injectable solution. Radioisotopes
are either
produced on-site in a cyclotron, in the case of short-lived [11C]carbon (half-
life 20 min) and
[18F]fluorine (half-life -110 min), or obtained from a commercial source
(e.g., MDS Nordion,
Ottawa, Canada) in the case of the iodine radioisotopes 1231, 1241, and 125!
[0047] The isolation and purification procedures (steps 4 through 6) are
common to all
radiolabeled compounds. The choice of the HPLC separation conditions (HPLC
column and
an appropriate solvent or solvent mixtures) is based on chemical properties of
the final
radiolabeled product and can be determined using standard analytical chemistry
techniques.
The unlabeled precursor compounds are either purchased or prepared using
standard
synthetic organic chemistry methods. Sigma-Aldrich provides numerous precursor
compounds. A number of benzoxazole compounds, and their syntheses, are
described in U.S.
7, 045,539; while Int'l Patent Appl., Pub. No. 2007/02400, describes the
preparation of
benzothiazole fluorinated derivatives and their use as in vivo imaging agents.
U.S. 7,250,525
discloses the synthesis of various radiolabeled stilbene derivatives. The
synthetic schemes in
each of these references are incorporated by reference herein in their
entirety. Different
-- 14 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
I radiolabeling agents, synthetic methodologies, reaction conditions, and work-
up procedures
are employed depending on the structural properties of the unlabeled
precursors.
[0048] The following types of procedures and agents are representative of
those used to
prepare the compounds listed in Tables 1 and 2.
[0049] Aromatic nucleophilic substitution with non-carrier-added [18F]fluoride
anion is
utilized in the case of polysubstituted phenols having a nitro (NO2) or a
halogen leaving
group in an ortho orpara position to an electron-withdrawing group such as
another nitro
group or a carbonyl group. The phenolic OH group has to be appropriately
protected (e.g. as
an alkyl or aryl ether). Examples 1 and 2 below illustrate this for the
preparation of 3-
[18F]fluoro-4-nitrophenol and 4-[ 18 F]fluoro-3-nitrophenol, respectively.
[0050] Aliphatic nucleophilic substitution with non-carrier-added
[18F]fluoride anion is
used in the case of phenolic compounds having halogen or activated sulfonate
ester leaving
groups on an alkyl group attached to the benzene ring directly or via a
heteroatom (N, 0, or
S). The phenolic OH group also has to be appropriately protected (e.g. as an
alkyl or aryl
ether). Typically, an activated sulfonate ester is used. Nonlimiting examples
include triflate
(trifluoromethanesulfonate), mesylate (methanesulfonate), and tosylate (4-
methylbenezenesulfonate).
[0051] Alkylation of an amino or hydroxyl group with [11C]methyl iodide or
triflate, or 2-
[18F]fluoroalkyl halide or tosylate prepared from non-carrier-added
[18F]fluoride anion, is
used for radiolabeling of the phenolic compounds with a primary amino group,
secondary
amino group, or an additional phenolic hydroxyl group. The phenolic OH group
has to be
appropriately protected.
[0052] Acylation of an amino or hydroxyl group with an acyl chloride
containing
[11C]carbonyl group. The phenolic OH group has to be appropriately protected.
[0053] Electrophilic aromatic substitution of a trialkylstannyl group on a
benzene ring of
a phenolic compound with carrier-added [18 F]F2 gas or acetyl hypofluorite.
The
trialkylstannyl group is introduced via an iodo group on the benzene ring.
[0054] Radioiodination proceeds in a similar manner to fluoride synthetic
routes.
Nucleophilic substitutions with [18F]fluoride anion. General procedure.
[0055] The choice of solvent and reaction temperature for the nucleophilic
substitutions
with [18F]fluoride anion depends on the chemical stability of the precursor
and on the
reactivity of the leaving group. In general, nucleophilic aromatic
substitution of a nitro group
requires heating in more polar solvents at higher temperatures, e.g. dimethyl
sulfoxide,
whereas the aliphatic nucleophilic substitution of a tosyloxy group on an
alkyl chain will
already proceed below the boiling point of acetonitrile.
[0056] 1. Preparation of [18F]fluoride salts: cyclotron-produced H[18F]F is
neutralized
with an appropriate base (e.g., cesium carbonate, silver carbonate, potassium
carbonate in the
-- 15 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 presence of potassium chelator Kryptofix 2.2.2, or tri- and tetraammonium
salts) and water is
removed by distillation, either in vacuo or by co-distillation with anhydrous
acetonitrile at
elevated temperature (above the boiling point of acetonitrile). An anhydrous
polar solvent
(e.g., acetonitrile, DMF, various sulfoxides and sulfones) is added to
dissolve the
[18F]fluoride salt for the radiolabeling reaction.
[0057] 2. An appropriately protected phenolic precursor, dissolved in the same
polar
solvent as used for dissolving the [18F]fluoride salt, is added and the
solution allowed to react
at elevated temperature (typical range 50 C to 220 C, depending on the
boiling point of the
solvent used) for a period of time ranging from 1 min to 30 min.
[0058] 3. Removal of inorganic salts including unreacted [1%F]fluoride salt is
achieved
by dilution of the reaction mixture with water and extraction of organic
components from the
water solution using a solid phase extraction cartridge.
[0059] 4. After elution from the solid phase extraction cartridge with a small
amount of
an organic solvent, the mixture is injected in an appropriate form onto a semi-
preparative or
preparative high performance liquid chromatography (HPLC) column (either with
normal or
reverse-phase solid phase) and separated using an appropriate solvent or a
solvent mixture.
[0060] 5. The radiolabeled product is detected using gamma detection, and the
HPLC
fraction containing the product is collected; the identity of the radiolabeled
product is
confirmed by co-injection with product carrying the common non-radioactive [F-
19]fluorine
using an analytical HPLC system.
[0061] 6. The HPLC solvent is removed either by evaporation in vacuo or, after
dilution
with water, by extraction with a solid-phase extraction cartridge. The
resulting product is
dissolved in a small amount of an appropriate solvent, most commonly ethanol,
and diluted
appropriately to get an injectable solution for human or other biological
applications. This
solution is sterilized by filtering it through a sterile 0.22 micron filter
into a sterile
multiinjection vial.
Alkylation with [11C]methyl iodide or triflate or with [18F]fluoroalkyl halide
or tosylate.
[0062] 1. [11C]Methyl iodide is prepared from cyclotron-produced [11C]carbon
dioxide
by LiA1H4 reduction to [ 11 C]methanol, followed by iodination with
concentrated hydroiodic
acid. An alternative route involves [11C]carbon dioxide reduction to["
C]methane in the gas
phase with hydrogen, followed by iodination with I2 at high temperature.
Preparation of
[11C]methyl triflate is achieved by reacting [11C]methyl iodide with solid
silver triflate.
[0063] As an example of a [18F]fluorine-containing alkylating agent, 2-
[18F]fluoro-l-
bromoethane can be prepared either from 1,2-dibromoethane or 2-bromoethyl
methanesulfonate by aliphatic nucleophilic substitution with non-carrier-added
[18F]fluoride
salts. (See, e.g., Satyamurthy N, Bida GT, Barrio JR, Luxen A, Mazziota JC,
Huang S-C,
Phelps ME. No-carrier-added 3-(2'-[18F]fluoroethyl)spiperone, a new dopamine
receptor-
binding tracer for positron emission tomography. Nucl Med Biol 1986;13:617-
624.)
-- 16 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [0064] 2. Once the alkylating agent has been radiolabeled, it is used to
alkylate an NH
or OH group on a precursor compound in an appropriate solvent in the presence
of a strong
base.
[0065] The isolation and purification steps are similar to those described
above for a
nucleophilic [18F]fluorination procedure.
Electrophilic aromatic substitution of a trialkylstannyl group on a benzene
ring of a phenolic
compound with carrier-added [18F]F? gas or acetyl hypofluorite.
[0066] The trialkylstannyl group is introduced in a reaction of a precursor
having an iodo
group on the benzene ring with hexamethylditin in the presence of tetrakis-
triphenylphosphine palladium (0) in an appropriate solvent (see, e.g.,
Namavari M, Bishop
A, Satyamurthy N, Bida G, Barrio JR. Regioselective radiofluorodestannylation
with [18F]F2
and [18F]CH3COOF: a high yield synthesis of 6-[ 18 F]fluoro-L-dopa. Appl
Radiat Isot 1992;
43:989-996).
Radioiodination.
[0067] Radioiodination of aromatic compounds by a various iodine radioisotopes
can be
performed using standard oxidative procedure starting from radioactive sodium
iodide salt
and chloramine-T as an oxidizer.
[0068] Once a radiolabeled tracer according to Table 1 and/or Table 2 is
prepared, it can
be used as described herein as a radiographically detectable substrate for one
or more SULTs.
Nonlimiting examples of in vivo radiographic techniques include PET (including
micro-PET)
and SPECT. In a variation of the method, one or more pharmacological or other
agents are
administered to the animal in vivo, and the effect of the agent(s) is
monitored. Optionally,
these techniques can be used on lab mammals in combination with
autoradiography and/or
scintillation counting in tissue acquired post-mortem from the sacrificed lab
animals.
[0069] For example, in one embodiment of the invention, a radiolabeled tracer
as
described herein is administered intravenously to a mammal and a dynamic study
is
performed to establish the time-dependent distribution of the tracer. Because
the radiolabeled
tracer is a substrate or inhibitor of at least one sulfotransferase, it
accumulates in one or more
organs, regions of an organ, or other tissues to an extent that is
proportional to the amount of
SULTs present there.
[0070] A particularly beneficial use of the invention is the administration of
one or more
SULT tracers capable of penetrating the blood-brain barrier to monitor SULT
distribution and
activity in the healthy, diseased, or injured brain of a human or other
mammal. In one
embodiment, a bolus of one or more radiolabeled tracers as listed in Table 1
and/or Table 2,
selected for its ability to cross the blood-brain barrier, is administered to
a human or other
mammal, and radiographic data indicative of tracer uptake in the subject's
brain is generated
by scanning the brain using a radiographic technique, (e.g., PET (including
micro PET),
-- 17 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 SPECT, etc.). The generated radiographic data can be used to probe or assess
SULT
distribution or activity in the subject's brain. Post-mortem techniques can
also be used.
[0071] It will be appreciated that a number of variations are included within
this aspect of
the invention. For example, in one embodiment, the therapeutic effect of a
pharmacological
or other agent on a sulfotransferase in a mammal is evaluated by (i)
administering to a
mammal a single bolus or multiple boluses of one or more radiolabeled tracers,
e.g., a tracer
recited in Table 1 and/or Table 2; (ii) generating a first set of radiographic
data by scanning
the mammal using a radiographic technique; (iii) administering to the mammal a
single bolus
or multiple boluses of an actual or putative therapeutic agent; (iv)
administering to a mammal
a single bolus or multiple boluses of a radiolabeled tracer, e.g., a tracer
recited in Table 1
and/or Table 2; (v) generating a second set of radiographic data by scanning
the mammal
using a radiographic technique; and (vi) comparing the first and second sets
of radiographic
data. In another embodiment, the method comprises (i) administering to a
mammal a bolus
of an actual or putative therapeutic agent; (ii) administering to the mammal a
bolus of a
radiolabeled tracer, e.g., a tracer as recited in Table 1 and/or Table 2;
(iii) generating a set of
radiographic data by scanning the mammal using a radiographic technique; and
(iv)
comparing the radiographic data to data obtained in the absence of the agent --
i.e., data
previously (or subsequently) obtained from the same mammal or from a different
mammal.
[0072] Advantageously, the radiographic technique can include, or be used in
conjunction
with, a computerized tomographic (CT) technique or magnetic resonance imaging
(MRI) to
scan or rescan all or part of the mammal's body, thereby providing an
anatomical
determination of the test animal and, hence, quantitation of tracer uptake
into tissues and
organs, both in the presence and in the absence of one or more pharmacological
or other
agents. Whole body, dynamic body, dynamic brain, and dynamic pelvic/abdominal
scans can
be carried out. Whole body micro PET in rodents can be employed to monitor
SULT
activity.
[0073] Optionally, additional information can be obtained by also
administering one or
more pharmacological or other agents to the animal, and monitoring the effect
of the agent(s)
on tracer uptake and distribution. Nonlimiting examples of suitable agents,
include
curcuminoids and cancer chemotherapy drugs. Any therapeutic agent can also be
used to
evaluate its potential role or effect on in vivo activity on SULTs in various
organs, or other
tissue using in vivo competitive kinetics with the radiolabeled tracer.
[0074] In another aspect of the invention, the effect of environmental
xenobiotics, such as
cigarette smoke, food, pollen, other allergens, irritants, polyaromatic
hydrocarbons (PAHs),
polychlorinated biphenyls (PCBs), and other known or suspected carcinogens,
etc., on SULT
distribution and activity is monitored in a way analogous to that described
herein for actual
and putative therapeutic compounds.
-- 18 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [0075] In another aspect of the invention, a tracer that has high affinity
for a first SULT,
but no or only low affinity for other SULTs, is utilized, allowing one to map
or probe
different metabolic pathways, as well as the effect of external agents on such
pathways. By
also administering a pharmacological or other agent to the mammal and
monitoring its effect
on SULT activity, one can better assess the agent's usefulness (and/or its
deleterious effect)
on the mammal.
[0076] Thus, the distribution/activity of any of the tracers listed in Table 1
can be
compared to that of any of the tracers from Table 2. Similarly, comparisons
can be made for
individual tracers within a given family (phenols, naphthols, etc.). Other
permutations and
variations are also within the scope of the inventions. As a specific example,
2-(4'-([11C]-
methylamino)phenyl)-6-hydroxybenzothiazole is a good marker of
sulfotransferases, most
specifically SULT IE1 (estrogen sulfotransferase), but it is not a substrate
for SULT 1A1. In
contrast, fluoronitrophenols are more specific for SULT IAl. Competition and
inhibition
studies can be conducted by administering 2-(4'-([ 11 C] -methylamino)phenyl)-
6-
hydroxybenzothiazole (e.g.) to a patient, scanning radiographically,
optionally administering
another pharmacological agent, and comparing the distribution/activity with
that for another
tracer described herein, e.g., a fluoronitrophenol.
[0077] Imaging methods and analytic methods currently practiced for FDG are
readily
utilized with the tracers described herein to assess SULT distribution and
activity. The
following references describe PET, micro-PET, and autoradiographic techniques
that will be
useful in practicing the invention: (1) Phelps M.E. PET Molecular imaging and
its biological
applications Springer, New York (2004), including Chapter 1. Cherry, S.R. &
Dahlbom, M.
PET Physics, Instrumentation and Scanners; Chapter 2 Gambhir, S.S.
Quantitative Assay
Development for PET; Chapter 4. Barrio, J.R. The molecular basis of disease;
Chapter 5,
Czernin, J. Oncological applications of FDG-PET; and Chapter 7. Silverman
D.H.S. &
Melega, W. P. Molecular imaging of biological process with PET. (2) Moore TH,
et al.
Quantitative assessment of longitudinal metabolic changes in after traumatic
brain injury in
the adult rat using FDG-microPET. J Cereb Blood Flow Metab. 20(10):1492-501,
(2000);
and (3) Matsumura A, et al. Assessment of microPET performance in analyzing
the rat brain
under different types of anesthesia: comparison between quantitative data
obtained with
microPET and ex vivo autoradiography. Neuroimage 20: 2040-2050 (2003).
[0078] The kinetics of tracer uptake is obtained by tracer kinetic modeling
(see for
example Carson R. E. Tracer Kinetic Modeling, in: Valk P.E. et al. Positron
Emission
Tomography, Springer, 2003, and Gambhir, S.S. Quantitative Assay Development
for PET,
in: Phelps M.E. PET Molecular imaging and its biological applications
Springer, New York,
2004; Bertoldo, A. et. al. (2005) J. Clinical Endocrinology & Metabolism,
90:1752-1759.
[0079] Quantitative comparisons of radiolabeled tracer uptake observed with
patients and
with normal control subjects will provide information about pathologies. For
example, in
-- 19 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 tumors that have increased levels of SULT (e.g. certain breast cancers), the
SULT tracers
described herein will be used to stage the tumor and to monitor the
effectiveness of surgery,
chemotherapy, and/or radiation therapy. Oral administration of the tracers
will provide
information about the functional activity of SULTs in the intestine, i.e.,
determination of the
amount of tracer uptake into the body provides a measure of functional
integrity of the
intestine in health and disease.
[0080] The use of tracers for in vivo monitoring of drug effects on SULTs
should allow
researchers to evaluate site of action, dose dependency, length of action and
other
pharmacokinetic and pharmacodynamic parameters of the drug in animals or human
subjects.
For example, in one embodiment of the invention, a radiolabeled tracer as
described herein is
administered to a subject, and PET imaging is used to monitor the effects of
drugs on the
absorption of tracer from the gut, the reabsorption of tracer from the
glomerular filtrate and
the uptake of tracer into organs, tissues and tumors. The imaging studies can
be carried out
before, during and after drug administration.
[0081] The invention provides a number of benefits, including use as a
diagnostic tool for
the detection of neurodegenerative diseases (e.g., Alzheimer's disease,
Parkinson's disease,
multiple sclerosis, and stroke); use as a diagnostic tool to evaluate the
evolution of disease in
patients who smoke or abuse drugs; and use as a tool to monitor the role of
therapeutic
interventions aimed at reducing inflammation by evaluating SULT expression in
vivo.
Examples
[0082] The following are nonlimiting examples of the invention.
[0083] A variety of non-radiolabeled, aromatic and heteroaromatic phenolic
compounds,
including 4'-substituted 2-phenyl-6-hydroxybenzothiazoles and similar fused
ring
compounds, were screened for their abilities to act as substrates for
sulfotransferases at
concentrations ranging from IOnM - 25 M. FIGS. 1-4 present sulfonation assay
data for 25
compounds. Table 3 provides sulfonation inhibition assay data for selected
compounds of
interest.
A. Materials
[0084] (3-Naphthol (BN, a reference control), para-nitrophenol (PNP),
estradiol (E2),
dehydroepiandrosterone (DHEA), dopamine, dithiothreitol (DTT), and MgC12 were
purchased from Sigma (St. Louis, MO). Cytosolic extract of sf-9 insect cells
infected with a
baculovirus containing SULT cDNAs (SULTIAI, SULTIA3, SULTIEl, SULT2A1) were
also purchased from Sigma. [35S]-3'-Phosphoadenosine 5'-Phosphosulfate
(PAPS)(1-
3Ci/mmol) was purchased from Perkin Elmer (Waltham, MA). Aluminum-backed
silica
TLC plates were purchased from Whatman.
[0085] Unlabeled compounds, nos. 1, 11, and 13 can be purchased from Aldrich
(Milwaukee, WI); no. 2 from Acros Organics (Morris Plains, NJ), and no. 9 from
TCI
American (Portland, OR). Compound nos. 3-8 and l Ocan be prepared as described
in the
-- 20 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
I following references: no. 3: J. Med Chem. 2004, 47, 4829; no. 4: Journal of
the Chemical
Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-
1999) (1982), (3), 815-21; no. 5: J. Heterocyclic Chem. 2000, 37, 1655 & Chem.
Phar. Bull.
1978, 26, 1443; no. 6: US Patent 6,130,217 (2000); no. 7: Synth. Comm.,
29(14), 2435-2445,
1999; Archiv der Pharmazie, 308 (7), 550-7, 1975; and JCS, PT I. (11), 2362-
70, 1980; no. 8:
WO 2004 108694 Al 2004; and no. 10: J. Med Chem. 2004, 47, 4829. Each of these
references is incorporated by reference herein in its entirety.
[0086] Unlabeled compounds nos. 13-25 can be prepared according to a general
methodology for preparing 4'-substituted 6-hydroxybenzothiazoles, using the
following three
approaches developed for the synthesis of 4'-alkylamino benzothiazoles
described by Mathis
and colleagues (2003). Some of these compounds are covered by their US patent
7,270,800
(incorporated by reference herein in its entirety) and related patents.
[0087] (a) Reaction of para-methoxybenzoyl chloride with para-substituted
anilines
results in formation of amides which are then converted into thioamides and
cyclized.
[0088] (b) Condensation of appropriately para substituted benzoic acids with 2-
amino-5-
methoxythiophenol in polyphosphoric acid.
[0089] (c) Condensation of appropriately para substituted benzaldehydes and 2-
amino-5-
methoxythiophenol in boiling dimethyl sulfoxide (DMSO).
[0090] The resulting 6-methoxybenzothiazoles are de-methylated with BBr3 to
form the
final 6-hydroxy compounds. Note: To make radiolabeled analogs of these
compounds,
radiosynthesis is performed using 2-(4'-aminophenyl)-6-hydroxybenzothiazole
(prepared as
described by Mathis et al., 2003) and [C-I I]methyl triflate (as described in
Solbach et al.,
2005).
B. Sulfonation Assays
[0091] Substrate sulfonation assays were performed using cytosolic
sulfotransferases
SULTIAI, SULTIA3, SULTIE1, and SULT2A1. Enzyme kinetic parameters were
determined by using substrate concentration curves. The sulfonation reaction
was carried out
using [35S] -PAPS as the sulfate donor, and the reaction mixture was analyzed
using a thin-
layer chromatography (TLC) method described in literature (Falany et al.,
2006). Reaction
mixtures consisted of 10 L of substrates, originally dissolved in dimethyl
sulfoxide and
diluted to 1% with Tris-HC1 buffer; 50mM Tris-HC1 buffer, pH 7.4; 0.1% bovine
serum
albumin; 7.5mM DTT; and 1 M [35S]-PAPS in the final volume of 50 L. The final
concentration of dimethyl sulfoxide was kept at 0.2%. Reactions with SULTIEI
and
SULT2A 1 were supplemented with 7mM MgC12; reactions with SULT 1 A3 included 1
mM
pargyline. Control reactions were performed under identical conditions without
addition of
substrates. Sulfonation reactions were carried out at 37 C for 15min.
Enzymatic activity was
terminated by precipitation with 50 L of ice cold methanol and cooling the
mixture at -20 C.
Subsequently, 20 L aliquots of the supernatant were spotted on silica gel TLC
plates and
-- 21 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
I were developed in t-butanol:acetic acid:water (8:1:1 by volume). Sulfonated
products
(Rf=0.66 0.05) were well separated from unreacted [35S]PAPS, which was
retained at the
origin. TLC plates were exposed on digital autoradiography plates for 2hrs and
read in with a
Fuji BAS-5000 digital autoradiography plate reader. The results were
quantitated with the
software provided with the scanner. Spots were localized and the silica gel
was scraped into
liquid scintillation vials. Vials were counted using MP-Ecolite+ LS fluid and
a Packard
Tricarb 2300TR LSC for 5min per vial. Reactions were monitored for linearity
with time and
enzyme concentration to ensure the enzyme was the limiting factor.
[0092] Sulfonation equilibrium constants (Km), maximum enzyme velocities
(Vma,), and
substrate efficay (Vmax/Km) were experimentally determined for the in vitro
enzymatic
sulfonation of the hydroxy group in each of the compounds listed in FIGS. 1-4
(Nos. 1-25)
with the sulfotransferases SULTIA1, SULTIA3 SULTIE1, and SULT2A1. "B.D.L."
denotes "below detection limit. The ratio Vmax/Km is a measure of substrate
catalytic
efficiency, based on the Michaelis-Menten equation, V= Vmax [S]/ Km +[S],
where [S]
denotes substrate concentration. The results show that 4'-substituted 2-phenyl-
6-hydroxy
fused azoles and structurally related compounds are specific SULTIEI
substrates. Their
efficacy, established by the Vm./Km ratio, is related to the electronegativity
of the substituent
at the para-aryl position.
[0093] In one embodiment of the invention, the data in FIGS. 1-4 is used to
select
compounds of interest for in vivo investigation of SULT distribution and/or
activity in
humans and other mammals. Thus, a compound is selected, radiolabeled using a
technique as
described above, and then administered to a human or other mammal. SULT
distribution/activity is observed using a radiographic imaging technique, as
described above.
C. Inhibition Assays.
[0094] In vitro inhibition reactions were performed using the standard SULTIAI
substrate, para-nitrophenol (PNP), against various 4'-substituted 2-phenyl-6-
hydroxy-
benzothiazoles shown in Table 3. PNP was dissolved in 50mM Tris-HCl buffer (pH
7.4), and
inhibitors were dissolved in dimethyl sulfoxide and diluted to I% dimethyl
sulfoxide
concentration with the Tris-HCl buffer. The reaction was carried out with
exactly the same
method as in the sulfonation assays, except 10 L of substrate was substituted
with 5 L of
PNP and 5 L of inhibitor. A standard curve for estimating Michaelis-Menten
kinetics with
PNP and sulfotransferase SULTIAI was performed initially followed by
additional curves in
the presence of increasing concentrations of inhibitor. The final methyl
sulfoxide
concentration was 0.2%. The results are presented in Table 1, wherein K;
denotes the
equilibrium constant for sulfonation inhibition.
Table'3. Inhibition of sulfotransferase SULTIAI sulfonation of 4-nitrophenol
by different 4'-substituted 2-phenyl-6-hydroxybenzothiazoles.
-- 22 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
RI
S
CCN
R2 R1 R2 R3 K; n
14 OH H -NH-CH3 5.1 0.3
17 OH H -OCH3 24 2
18 OH H -NH-C =0 -CH3 100 20
19 OH H F 140 10
[0095] A small value of Ki denotes greater sulfotransferase inhibition.
Notably, the
benzothiazoles listed in Table 1, which are specific substrates for SULTIEI
and not
substrates for SULTIAI (or any other tested SULT), are excellent inhibitors of
SULTIAI.
These compounds can be radiolabeled (with, e.g., 11C, 18F, 125I, etc.) using
the synthetic
methodologies described above.
Example 1. Synthesis of 44 18F1Fluoro-3-nitrophenol, (1-3)
Precursor preparation (4-chloro-1-(methoxymethoxy)-3-nitrobenzene, 1-1).
[0096] To a solution of 4-chloro-3-nitrophenol (173 mg, 1 mmol) and
chloromethyl
methyl ether (0.15 mL, 2 mmol) in dichloromethane (1 mL) was added
triethylamine (0.3
mL, 2.2 mmol). The light yellow solution was stirred at room temperature for
25 min and
then evaporated. The yellow oil was purified by column chromatography (40g
silica gel)
with hexane/ethyl acetate (6:4) resulting in 133 mg of 4-chloro-1-
(methoxymethoxy)-3-
nitrobenzene (1-1) as a yellow oil. It was further purified by semi-
preparative HPLC (Alltech
Econosil Silica l0 , 10x250 mm; CH2C12/hexane 7:3, 4 mL/min; X=254 nm; RT =
8.0 min).
The HPLC product fraction was washed twice with water, dried with sodium
sulfate and
evaporated. The slight yellow precursor was further dried with co-evaporated
with 2x0.5 mL
of acetonitrile and dried under high vacuum for 1 hour.
0 0 '_~CH3 0 ~-0 "'CH3
Cs [F-18]F
Kryptofix 222 conc. HBr
DMSO
NO2 160 C NO2 NO2
CI [F-18]F [F-18]F
1-1 1-2 1-3
-- 23 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
I Radiofluorination.
[0097] Cyclotron-irradiated [180] -enriched water containing H[18F]F was mixed
with a
solution of 2.1 mg of cesium carbonate in 0.1 mL of water and 0.5 mL of
acetonitrile. The
volatile components were evaporated under a stream of nitrogen at 115 C and
the residual
moisture was co-evaporated with 3 x 0.5 mL of acetonitrile. The precursor 4-
chloro-l-
(methoxymethoxy)-3-nitrobenzene (1-1; 6 mg) in 0.5 mL of dimethylsulfoxide was
added
and the mixture was heated at 160 C for 10 min.
[0098] The reaction mixture was cooled in air for 2 min, then 3 mL of cold 0.1
N
hydrochloric acid was added. The resulting mixture was passed through a C18
Sep-Pak
cartridge, which was previously activated with 5 mL of methanol and washed
with 12 mL of
water. The Sep-Pak cartridge was washed twice with 6 mL of water and the
retained product
was eluted with 1.2 mL of methanol. To the methanol solution was added 0.8 mL
of 37%
HCl and heated at 100 C for 5 min. The resulting solution was neutralized with
0.8 mL of
11.5 M sodium hydroxide and injected onto a semi-preparative HPLC column
(Waters
Symmetry Prep C18 7 , 7.8 x 300 mm; MeCN/H20 15:85, 6 mL /min; 254 Mn).
[0099] The product fraction (RT = 35 min) was collected, diluted with the same
volume
of brine and passed through a C18 Sep-Pak cartridge, pre-washed with 5 mL of
ethanol and
2x5 mL of water. The Sep-Pak cartridge was washed twice with 5 mL of saline
and the
radioactive product was eluted with 0.3 mL of ethanol. In this way 15-57 mCi
(6 - 23%
radiochemical yield EOS) of the final product was isolated after 2 hour
synthesis time.
[00100] The radioactive and chemical purities of 4-[ 18 F]fluoro-3-nitrophenol
(1-3) exceed
95% and were determined on a Waters Symmetry C18 analytical HPLC column (5 ,
4.6 x 150
mm), using tetrahydrofuran, methanol and water mixture (40:20:40) with flow
rate at 0.5
mL/min, by radioactivity and UV absorption detection (254nm). The retention
time of 4-
[18F] fluoro-3-nitrophenol under these conditions is 12 min. The specific
radioactivity was
determined to be 3,500-5,000 Ci/mmol at the end of synthesis (EOS).
Example 2. Synthesis of 34 18Flfluoro-4-nitrophenol (2-3)
A. Precursor preparation (3,4-dinitromethoxybenzene, 2-1).
[00101] 3,4-Dinitrophenol (370 mg, 2 mmol) was dissolved in a mixture of 120
mg of
sodium hydroxide (3 mmol) and 5 mL of water. Methyl sulfate (255 mg, 2 mmol)
was
slowly added and the mixture heated under reflux for 2 hours. The reaction
mixture was
neutralized by hydrochloric acid and extracted with ethyl acetate. The organic
phase was
washed with water, dried over magnesium sulfate and evaporated in vacuum. The
remaining
reddish oil was purified by column chromatography on silica gel using hexane
and ethyl
acetate as mobile phase. 3,4-Dinitromethoxybenzene (2-1) (198 mg, 72%) was
isolated as a
reddish solid.
-- 24 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [00102] The product was further purified using HPLC (Whatman Partisil silica
column, 10
m, 10x500 mm) with ethyl acetate and hexane as mobile phase.
0I.-ICH3 0I-ICH3 iH
K [F-18]F
Kryptofix 222 conc. HBr
DMSO
NO2 145-150 C [F-18]F [F-18]F
NO2 NO2 NO2
2-1 2-2 2-3
B. Radiolabeling
[00103] Cyclotron-irradiated [180] -enriched water containing H[18F]F was
mixed with a
solution of 1 mg of potassium carbonate and 10 mg of Kryptofix 2.2.2 in 0.04
mL of water
and 0.96 mL of acetonitrile. Water and acetonitrile were evaporated at 105 C
under a stream
of nitrogen and the residual moisture was co-evaporated three times with 0.5
mL of
anhydrous acetonitrile. The precursor 3,4-dinitromethoxybenzene (2-1; 5 mg) in
1 mL of
anhydrous dimethylsulfoxide was added and the mixture was heated at 145-150 C
for 15 min.
After 1 min of cooling in air, 3 mL of water was added and the mixture
extracted using a C18
SepPak solid phase extraction cartridge, which was activated with 6 mL of
ethanol followed
by 12 mL of water. The crude mixture was eluted with 1.0 mL of
tetrahydrofuran/methanol
mixture (1:1), diluted with 1.5 mL of 50 mM sodium phosphate buffer (pH=8.0)
and injected
onto Waters Symmetry Prep C18 semi-preparative HPLC column (7 m, 7.8x300 mm).
[00104] The methoxybenzene 2-2 was eluted with a mixture of tetrahydrofuran,
methanol,
and sodium phosphate buffer (50 mM, pH=8.0) (25:15:60, respectively) with a
flow rate 3
mL/min. 3-[18F]fluoro-4-nitromethoxybenzene (2-2) was isolated as a single
radioactive peak
at -20 min. The fractions containing methoxybenzene 2-2 were collected,
diluted with 5 mL
of water and passed through a Waters C18 SepPak solid phase extraction
cartridge, activated
with 5 mL of ethanol followed by 10 mL of water. After extraction, 3-
[18F]fluoro-4-
nitromethoxybenzene was eluted with 6 mL of 10% methanol in ethyl acetate, the
eluate
collected and evaporated to dryness at 50-60 C under a stream of nitrogen. 2
mL of 48%
hydrobromic acid was added and the mixture heated in a closed vessel at 145-
150 C for 15
min.
[00105] After cooling the mixture was neutralized by addition of 1.25 mL of
20% sodium
hydroxide, diluted with 2 mL of water and extracted using a C18 SepPak solid
phase
extraction cartridge, which was activated with 6 mL of ethanol followed by 12
mL of water.
After an additional 10 mL water wash, the cartridge was eluted with 1 mL of
tetrahydrofuran,
the eluate mixed with 2 mL of sodium phosphate buffer (50 mM, pH=8.0) and
injected onto
Waters Symmetry Prep C18 semi-preparative HPLC column (7 m, 7.8x300 mm). The
-- 25 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 product was eluted as a single peak at -12 min with a mixture of
tetrahydrofuran and sodium
phosphate buffer (50 mM, pH=8.0) (20:80, respectively) at 2 mL/min (X=254 nm).
[00106] The product fraction (15-20 mCi) was collected, diluted with the same
volume of
brine and passed through a C18 Sep-Pak cartridge, pre-washed with 5 mL of
ethanol and 10
mL of water. The Sep-Pak cartridge was washed twice with 5 mL of saline and
the
radioactive product was eluted with 0.5 mL of ethanol. In this way 5-10 mCi (2
- 4%
radiochemical yield EOS) of the final product was isolated after 3 hour total
synthesis time.
[00107] The radioactive and chemical purities of 3-[ 18 F]fluoro-4-nitrophenol
exceed 95%
and were determined on a Waters Symmetry C18 analytical HPLC column (5 , 4.6 x
150
mm), using tetrahydrofuran and phosphate buffer (50 mM, pH=8.0) (20:80,
respectively)
with flow rate at 0.5 mL/min, by radioactivity and UV absorption detection
(254nm). The
retention time of 3-[ 18 F]fluoro-4-nitrophenol under these conditions was 9
min. The specific
activity was 2,500-4,000 Ci/mmol at EOS.
Example 3 Use of a Tracer for In vivo Mapping and Analysis of Function of
SULTs
in Non-Human Mammals
[00108] A bolus of a radiolabeled tracer is administered intravenously to a
non-human
primate, rodent, or other non-human mammal, and the distribution of tracer
transport activity
is followed by radiographic means, e.g., PET, microPET and/or SPECT. For PET,
an
intravenous dose of the tracer contains - 0.1-3 mCi/kg (body weight) dissolved
in < 1ml of
10% ethanol in saline. The identity of each organ and tissue taking up the
tracer can be
confirmed by CT scans. Scans can be conducted both with and without
administering one or
more pharmacological agents, e.g., 2, 6-dichloro-4-nitrophenol, quercitin,
curcumin, etc.
[00109] Figure 5 depicts in vivo microPET imaging of sulfotransferase SULTIE1
expression in healthy and inflamed lungs in 8-9 month old male Sprague-Dawley
rats, using
the substrate 2-(4'-([11C]-methylamino)phenyl)-6-hydroxybenzothiazole. On the
left are
shown the chest and upper abdomen of a healthy control rat; on the right is a
rat suffering
from renal hypertension, chronic progressive nephropathy, and lung
inflammation. Both
animals were injected with 2.0-2.5 mCi of activity. The images shown were
acquired over
the period of 15-25 min after injection. Liver metabolizes the tracer rapidly
(-90% is in
sulfated form after 10-15 min in plasma) and contains a high level of
activity. The lungs in
the healthy rat are indistinguishable from the background. In contrast, the
lungs in the rat
with lung inflammation show increased uptake. Warmer colors represent higher
levels of
tracer uptake.
[00110] Metabolite analysis was performed using reverse phase C-18 TLC plates
and a
mixture of methanol, acetic acid and water (80:5:15, respectively). Plasma was
de-
proteinated with addition of an equal volume of methanol. The supernatant was
spotted on
the plates and the plates developed in the mobile phase. The analysis of the
plates was
-- 26 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
I performed as described above in the description of the sulfonation assays
(Ex. 1-25).
Metabolites were identified as follows: 100 mL samples of plasma were mixed
with 500-
1000U of either steroid sulfotransferase (to remove the sulfonated metabolite)
or
glucoronidase (to remove glucoronidated metabolite). The reaction mixtures
were incubated
at 37 C for 15 min and the reactions were stopped by addition of 200 mL of ice
cold
methanol. The supernatants were analyzed as described above and the results
compared with
the results for un-treated plasma.
[00111] Figure 7 depicts in vivo microPET imaging of sulfotransferase activity
and
inhibition in a male, Sprague-Dawley rat suffering from renal hypertension,
chronic
progressive nephropathy, and lung inflammation, using 4-[18F]-fluoro-3-
nitrophenol as a
substrate and 2,6-dichloro-4-nitrophenol as an inhibitor. 4-[18F]-fluoro-3-
nitrophenol was
administered as a bolus injection (0.5 to 2.0 mCi) and the rat brain was
scanned dynamically
for 60 min. Subsequently, the chest was scanned for 5 min., followed by a 5
min. scan of the
abdomen. The microPET images in the top row clearly show that 4-[18F]-fluoro-3-
nitrophenol is a substrate for the sulfotransferase SULTIAI. (Warmer colors
indicate a
higher amount PET activity, indicative of tracer uptake and interaction with
SULTIAI.) The
lower row shows the inhibitory effect on SULT 1 Al activity caused by
administering a 5
mg/Kg dose of 2,6-dichloro-4-nitrophenol at the time of the 4-[ 18 F]-fluoro-3-
nitrophenol
bolus injection.
Example 4: Use of a Tracer for In vivo Mapping and Analysis of Function of
SULTs
in Humans
[00112] A bolus of a radiolabeled tracer is administered to a human subject by
intravenous
injection, and its uptake into a tumor (in the case of cancer), one or more
organs of interest,
and/or other tissues of the body is followed radiographically. For a 50-70 kg
person, 10 mCi
of an appropriate tracer from Table 1 or 2 (e.g.) is dissolved in < l Oml 10%
ethanol in saline
and is injected intravenously, and the distribution of the tracer is followed
dynamically with
PET for up to 2 hours (multiple whole-body scans at different time intervals
or dynamic PET
scan of a specific organ). SULT activity in organs and tissues is determined
using tracer
kinetic modeling from the PET determined tracer uptake data. The anatomical
location of
tracer uptake in both normal subjects and cancer patients can be determined
using CT scans.
[00113] Figure 6 depicts in vivo PET imaging of sulfotransferase SULTIEI
expression in
two adult male humans. The left image shows the chest and upper abdomen of a
45 year old
smoker, while the right image shows a 69 year old non-smoker. Increased
SULTIEI
expression associated with lung inflammation caused by smoking is clearly
visible in the
lungs of the smoker.. Both subjects were scanned with PET 20-45 minutes after
being
injected with the tracer 2-(4'-([11C]-methylamino)phenyl)-6-
hydroxybenzothiazole. The
smoker received a dose of 10.5 mCi, and the non-smoker received 10.0 mCi. The
images
were normalized by dividing the signal values with dose injected per kg of
body weight.
-- 27 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
I Liver and kidneys, the organs which metabolize and excrete the tracer, show
high level of
activity. Lungs show increased level of uptake compared with the background
(muscles).
Example 5 Use of a Tracer for In vivo Monitoring of a Therapeutic Intervention
[00114] A radiolabeled tracer is administered to a human or other mammal
enterally or
parenterally, e.g., as an oral dose or intravenous injection, and whole body
PET scans are
recorded for up to 2 hours. A therapeutic drug (e.g. curcumin or other
curcuminoid,
chemotherapeutic agents that target tumors, etc.) or drug candidate is also
administered to the
subject by an appropriate mode of delivery, and its effect on tracer uptake is
monitored. The
drug or drug candidate is administered at one or more times before and/or
after the start of the
PET scan. In this manner, the time, dosage, and route of administration and
distribution of
the drug and its effect on tracer uptake into organs and tissues is precisely
determined based
on the PET scan and using tracer kinetic modeling.
Example 6 Use of a Tracer for In vivo Monitoring of the Effect of a Xenobiotic
[00115] A radiolabeled tracer is administered to a human or other mammal
enterally or
parenterally, e.g., as an oral dose or intravenous injection, and whole body
PET scans are
recorded for up to 2 hours. An environmental xenobiotic, such as cigarette
smoke, food,
pollen, other allergens, irritants, polyaromatic hydrocarbons (PAHs),
polychlorinated
biphenyls (PCBs), and other known or suspected carcinogens, etc. is also
administered to the
subject by an appropriate mode of delivery, and its effect on tracer uptake is
monitored. The
xenobiotic is administered at one or more times before and/or after the start
of the PET scan.
In this manner, the time, dosage, and route of administration and distribution
of the
xenobiotic and its effect on tracer uptake into organs and tissues is
precisely determined
based on the PET scan and using tracer kinetic modeling.
[00116] The invention has been described with reference to various embodiments
and
examples, but is not limited thereto. Variations may be made without departing
from the
invention, which is limited only by the appended claims and equivalents
thereof.
References
[00117] The following references are incorporated herein in their entirety:
[00118] Agdeppa ED, Kepe V, Liu J, et al. 2-Dialkylamino-6-acylmalorionitrile
substituted naphthalenes (DDNP Analogs): novel diagnostic and therapeutic
tools in
Alzheimer's disease. Mol Imaging Biol 2003a; 4:404-417.
[00119] Agdeppa ED, Kepe V, Petrie A, et al. In vitro detection of (S)-
naproxen and
ibuprofen binding to plaques in the Alzheimer's brain using the positron
emission
tomography molecular imaging probe 2-(1-[6-[(2-
[(18)F]fluoroethyl)(methyl)amino]-2-
naphthyl]ethylidene)malononitrile. Neuroscience 2003; 117:723-730.
[00120] Baran H, Jellinger K. Human brain phenolsulfotransferase. Regional
distribution
in Parkinson's disease. J Neural Transm [P-D Sect] 1992; 4:267-276.
-- 28 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [00121] Boccia S, Persiani R, La Torre G, Rausei S, Arzani D, Gianfagna F,
Romano-
Spica V, D'Ugo D, Ricciardi G. Sulfotransferase lAI polymorphism and gastric
cancer risk:
a pilot case-control study. Cancer Lett 2005; 229:235-243.
[00122] Boccia S, Cadoni G, La Torre G, Arzani D, Volante M, Cattel C,
Gianfagna F,
Paludetti G, Almadori G, Ricciardi G. A case-control study investigating the
role of
sulfotransferase 1A1 polymorphism in head and neck cancer. J Cancer Res Clin
Oncol 2006;
132:466-472.
[00123] Burchell B, Coughtrie MW. Genetic and environmental factors associated
with
variation of human xenobiotic glucuronidation and sulfation. Environ Health
Perspect 1997;
105:739-747.
[00124] Ebmeier CC, Anderson RJ. Human Thyroid Phenol Sulfotransferase Enzymes
IA1 and 1A3: Activities in Normal and Diseased Thyroid Glands, and Inhibition
by Thyroid
Hormones and Phytoestrogens. J Clin Endocrin Metabol 2004; 89:5597-5605.
[00125] Eisenhofer G, Coughtrie MW, Goldstein DS. Dopamine sulphate: and
enigma
resolved. Clin Exp Pharmacol Physiol Suppl 1999; 26:S41-S53.
[00126] Falany CN. Enzymology of human cytosolic sulfotransferases. FASEB J
1997;
11:206-216.
[00127] Falany JL, Pilloff DE, Leyh TS, Falany CN. Sulfation of raloxifene and
4-
hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos.
2006; 34:361-
8.
[00128] Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL,
McManus ME. Human sulfotransferases and their role in chemical metabolism.
Toxicol Sci
2006; 90:5-22.
[00129] Glatt H, Boeing H, Engelke CEH, Ma L, Kulhow A, Pabel U, Pomplun D,
Teubner W, Meinl W. Human cytosolic sulphotransferases: genetics,
characteristics,
toxicological aspects. Mutat Res 2001; 482;27-40.
[00130] Glatt H. Activation and inactivation of carcinogens and mutagens by
human
sulfotransferases. In `Human Cytosolic Sulfotransferases'; Pacifici GM and
Coughtrie MWH,
Eds. Taylor & Francis; Boca Raton, London, New York, Singapore; 2005, pp. 279-
304.
[00131] Hempel N, Barnett A, Gamage N, Duggleby RG, Windmill KF, Martin JL,
McManus ME. Human SULTIA SULTs. In `Human Cytosolic Sulfotransferases';
Pacifici
GM and Coughtrie MWH, Eds. Taylor & Francis; Boca Raton, London, New York,
Singapore; 2005, pp. 179-230.
[00132] Kepe V, Shoghi-Jadid K, Wu H-M, et al. Global and regional [F-18]FDDNP
binding as in vivo measure of Alzheimer's disease neuropathology. J Nucl Med
2004;45Suppl:126P.
[00133] Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in
Alzheimer's
disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319.
-- 29 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [00134] Liyou EN, Buller KM, Tresillian MJ, Elvin CJ, Scott HL, Dodd PR,
Tannenberg
AEG, McManus ME. Localization of a brain sulfotransferase, SULT4A1, in the
human and
rat brain: an immunohistochemical study. J Histochem Cytochem 2003; 51:1655-
1664.
[00135] Mathis CA, Wang Y, Holt DP, Huang G-F, Debnath ML, Klunk WE. Synthesis
and Evaluation of 11 C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid
Imaging
Agents. J Med Chem 2003;46:2740-2754.
[00136] Mathis CA, Holt DP, Wang Y. Huang GF, Debnath ML, Shao L. Klunk WE.
Species-dependent metabolism of the amyloid imaging agent [C-11 ]PIB. J Nucl
Med 2004;
45Suppl:114P.
[00137] Miki Y, Nakata T, Suuki T, Darnel AD, Moriya T, Kaneko C, Hidaka K,
Shiotsu
Y, Kusaka H, Sasano H, Systemic Distribution of Steroid Sulfatase and Estrogen
Sulfotransferace in Human Adult and Fetal Tissue, J. Clin. Endocrin. & Metab.
87(12):5760-
5768 (2002).
[00138] Pacifici GM, Quilici MC, Giulianetti B, Spisni R, Nervi M, Guilianu L,
Gomeni
R. Ritodrine sulfation in the human liver and duodenal mucosa: interindividual
variability.
Eur J Drug Metab Pharmacokin 1998;23:64-74.
[00139] Pacifici GM. Sulfation of drugs. In `Human Cytosolic
Sulfotransferases'; Pacifici
GM and Coughtrie MWH, Eds. Taylor & Francis; Boca Raton, London, New York,
Singapore; 2005, pp. 157-177.
[00140] Robbins PW, Lippman F. Identification of enzymatically active sulfate
as
adenosine-3'-phosphate-5'-phosphosulfate. J Am Chem Soc 1956; 78:2652-2654.
[00141] Saksela 0, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived
heparan
sulfate binds basic fibroblast growth factor and protects it from proteolytic
degradation. J Cell
Biol 1988; 107:743-751.
[00142] Seibert C, Cadene M, Sanfiz A, Chait BT, Sakmar TP. Tyrosine sulfation
of
CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a
discrete
pattern and temporal sequence. Proc Natl Acad Sci USA 2002; 99:11031-11036.
[00143] Shatalova EG, Walther SE, Favorova 00, Rebbeck TR, Blanchard RL.
Genetic
polymorphisms in human SULTIAI and UGT1A1 genes associate with breast tumor
characteristics: a case-series study. Breast Cancer Res 2005; 7:R909-R921.
[00144] Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of
neurofibrillary
tangles and beta-amyloid plaques in the brains of living patients with
Alzheimer disease. Am
J Geriatr Psychiatry 2002; 10:24-35.
[00145] Solbach C, Uebele M, Reischl G, H.-J. Machulla H-J. Efficient
radiosynthesis of
carbon-11 labeled uncharged Thioflavin T derivatives using [11C]methyl
triflate for f3-
amyloid imaging in Alzheimer's Disease with PET. Appl Radiat Isotop
2005;62:591-595.
-- 30 --

CA 02706017 2010-05-18
WO 2008/121407 PCT/US2008/004205
1 [00146] Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S,
Hirakawa
H, Kimura M, Sasano H. Estrogen sulfotransferase and steroid sulfatase in
human breast
carcinoma. Cancer Res 2003; 63:2762-2770.
[00147] van Horssen J, Wesseling P, van den Heuvel LPWJ, de Waal RMW, Verbeek
MM. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related
disorders.
Lancet Neurol 2003; 2: 482-492.
[00148]
[00149] Vargas F, Frerot 0, Brion F, Trung Tuong MD, Lafitte A, Gulat-Marnay
C. 3'-
Phosphoadenosine 5'-phosphosulfate biosynthesis and the sulfation of
cholecystokinin by the
tyrosylprotein-sulfotransferase in rat brain tissue. Chem Biol Interact 1994;
92:281-291.
[00150] Verbeek MM, Otte-Holler I, van den Born J, van den Heuvel LPWJ, David
G,
Wesseling P, de Waal RMW. Agrin Is a Major Heparan Sulfate Proteoglycan
Accumulating
in Alzheimer's Disease Brain. Am J Pathol, 1999; 155:2115-2125.
[00151] Verhoeff NP, Wilson AA, Takeshita S, et al. In vivo imaging of
Alzheimer disease
beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004; 12:584-595.
[00152] Vietri M, Vaglini F, Cantini R, Pacifici GM. Quercitin inhibits the
sulfation of R(-
)-apomorphine in human brain. Int J Clin Pharmacol Ther 2002; 41:30-35.
[00153] Wang Y, Spitz MR, Tsou AM-H, Zhang K, Makan N, Wu X. Sulfotransferase
(SULT) 1Al polymorphism as a predisposition factor for lung cancer: a case-
control
analysis. Lung Cancer 2002; 35:137-142.
[00154] Wu M-T, Wang Y-T, Ho C-K, Wu D-C, Lee Y-C, Hsu H-K, Kao E-L, Lee J-M.
SULTIAI polymorphism and esophageal cancer in males. Int J Cancer 2003;
103:101-104.
[00155] Xu D, Tiwari V, Xia G, Clement C, Shukla D, Liu J. Characterization of
heparan
sulphate 3-0-sulphotransferase isoform 6 and its role in assisting the entry
of herpes simplex
virus type 1. Biochem J. 2005; 385:451-459.
[00156] Young WF, Okazaki H, Laws Jr. ER, Weinshilboum RM. Human brain phenol
sulfotransferase: biochemical properties and regional localization. J
Neurochem 1984;
43:706-715.
[00157] Van Zante A, Rosen SD. Sulphated endothelial ligands for L-selectin in
lymphocyte homing and inflammation. Biochem Soc Trans 2003; 31:313-317.
[00158] Von der Kammer H, Pohlner J. Diagnostic and therapeutic use of a
sulfotransferase for neurodegenerative diseases. WO 2005/030947.
[00159] We acknowledge the assistance of Dr Gyochang Keum for synthesizing
many of
the compounds presented in this patent application, and Graham Cole (graduate
student,
Biomedical Physics Program, UCLA) for performing the in vitro enzymatic
determinations
with sulfotransferases shown in this application.
-- 31 --

Representative Drawing